AU717753B2 - Methods of improving allograft or xenograft tolerance by administration of an LFA-3 or CD2 binding protein - Google Patents

Description

I,

S F Ref: 268720D1

AUSTRALIA

PATENTS ACT 1990 COMPLETE SPECIFICATION FOR A STANDARD PATENT

ORIGINAL

99 9 9.

'.9 9. 9* 9.

Name and Address of Applicant: Actual Inventor(s): Address for Service: Invention Title: Biogen, Inc.

14 Cambridge Center Cambridge Massachusetts 02142 UNITED STATES OF AMERICA Barbara Wallner and Christopher D. Benjamin Spruson Ferguson, Patent Attorneys Level 33 St Martins Tower, 31 Market Street Sydney, New South Wales, 2000, Australia Methods of Improving Allograft or Xenograft Tolerance by Administration of an LFA-3 or CD2 Binding Protein The following statement is a full description best method of performing it known to me/us:of this invention, including the 5845 Methods of Improving Allograft or Xenograft Tolerance by Administration of An Lfa-3 Or Cd2 Binding Protein Technical Field of Invention The present invention relates to methods of improving tolerance of transplanted xenograft tissue or allograft tissue by administration of LFA-3 or CD2 binding proteins in mammals, including humans.

Background of the Invention An allograft is tissue that is transplanted between genetically nonidentical members of the same species. Allografts or organs such as the heart, kidney, liver, pancreas, cornea, bone marrow, lung and skin have become an increasingly successful and accepted medical practice for the treatment of various end stage diseases. The resulting increase in demand for transplants, unfortunately, has not been matched by an increase in the present donor supply, and efforts to increase the supply of human donors are not predicted to match the rising demand for human organs. For example, only 2,000 of the 14,000 patients per year who are eligible for a cardiac allograft actually receive a heart transplant in the United States (Rose, "Risks of *9 *9 9 9..

9.

9 99 e.

o 9 9 [N:\LIBUU]00844:JOC 2 Cardiac Transplantation", Ann. Thorac. Surg., 47, p. 615 (1989)).

Consequently, interest has increased in alternative sources for donor organs. One such alternative source is xenografts, which are transplants of tissue from one species to another species.

A problem for both allografts and xenografts is rejection of the donor graft tissue by the recipient. Graft rejection is the result of a complicated and not fully understood chain of events in the immune system. There are generally two facets of the immune response: 1) a cell mediated response, primarily comprising cytotoxic T cells which attack and kill foreign cells or virus-infected cells; and 2) a humoral response, comprising the activation of B cells to plasma cells which secrete antibodies specific for foreign macromolecules.

Graft rejection is histologically characterized by the progressive infiltration of 20 mononuclear cells, including lymphocytes, into the foreign tissue. The increased presence of these cells precedes the destruction of the graft by several days.

Sa Sensitized T lymphocytes, therefore, appear to be the principal initiators of the rejection process.

25 T lymphocytes play a major role in the immune response by interacting with target and antigenpresenting cells. For example, T lymphocyte-mediated killing of target cells is a multi-step process involving, initially, adhesion of cytolytic T lymphocytes (the effector cells) to target cells, such as graft endothelium. Also, helper T lymphocytes S. help initiate the immune response by adhesion to antigen-presenting cells within the graft tissue.

These interactions of T lymphocytes with target and antigen-presenting cells are highly specific 3 and depend on the recognition of an antigen on the surface of a target or antigen-presenting cell by one of the many specific antigen receptors on the surface of T lymphocytes.

The receptor-antigen interaction of T lymphocytes and other cells is also facilitated by various T lymphocyte surface proteins, the antigen-receptor complex CD3 and accessory molecules such as CD4, LFA-1, CD8, and CD2. It is also affected by accessory molecules such as LFA-3, ICAM-1 and MHC that are expressed on the surface of the target or antigen-presenting cells.

The interaction between CD2 and LFA-3 remains poorly understood with respect to activation of T cell activity. Recent studies have suggested that there is a specific interaction between CD2 (a T lymphocyte accessory adhesion molecule) and LFA-3 (a target cell and antigen presenting cell accessory molecule) which mediates T lymphocyte adhesion to the target or antigen 20 presenting cell. This cell-cell adhesion has been implicated in the initiation of T lymphocyte functional Sresponses (Dustin et al., "Purified Lymphocyte Function Associated Antigen 3 Binds To CD2 And Mediates T lymphocyte Adhesion," J. Exp. Med., 165, pp. 677-92 25 (1987); Springer et al., "The Lymphocyte Function-associated LFA-1, CD2, and LFA-3 Molecules: ell Adhesion Receptors of the Immune System", Ann.

Rev. Immunol., 5, pp. 223-52 (1987)). The LFA-3/CD2 interaction also plays a role in mediating T lymphocyte 30 interactions with thymic epithelial cells, in antigenindependent and dependent conjugate formation and in T lymphocyte rosetting with erythrocytes (see, e.g., Seed et al., "Molecular Cloning Of The CD2 Antigen, the T-Cell Erythrocyte Receptor, By a Rapid Immunoselection 4 Procedure", Proc. Natl. Acad. Sci. USA, 84, pp. 3365-69 (1987)).

LFA-3, which is found on the surface of a wide variety of cells, including human erythrocytes has become the subject of a considerable amount of study to further elucidate its role in various T lymphocyte interactions (see, Krensky et al., "The Functional Significance, Distribution, and Structure of LFA-1, LFA-2, and LFA-3: Cell Surface Antigen Associated with CTL-Target Interactions", J. Immunol., 131(2), pp. 611-16 (1983); Shaw et al.

"Two Antigen-Independent Adhesion Pathways Used by Human Cytotoxic T-cell Clones", Nature, 323, pp. 262-64 (1986)). Two natural forms of LFA-3 have been identified. One form of LFA-3 ("transmembrane LFA-3") is anchored in the cell membrane by a transmembrane hydrophobic domain. cDNA encoding this form of LFA-3 has been cloned and sequenced (see,. Wallner et al., "Primary Structure of Lymphocyte 20 Function-Associated Antigen-3 J. Exp. Med.

166, pp. 923-32 (1987)). Another form of LFA-3 is Sanchored to the cell membrane via a covalent linkage to phosphatidylinositol ("PI")-containing glycolipid.

This latter form has been designated "PI-linked LFA-3", 25 and cDNA encoding this form of LFA-3 has also been cloned and sequenced (Wallner et al., PCT publn.

WO 90/02181).

The human CD2 (T11) molecule is a 50 kD surface glycoprotein expressed on >95% of thymocytes and virtually all peripheral T lymphocytes.

Biochemical analyses using specific monoclonal antibodies have suggested that CD2 is T lineagespecific and exists on the cell surface in several differentially glycosylated forms (Howard et al.,

"A

Human T Lymphocyte Differentiation Marker Defined by 5 Monoclonal Antibodies that Block E-Rosette Formation", J. Immunol., 126, pp. 2117-22 (1981); Brown et al., in Leukocyte Typing III, ed. McMichael, Oxford University Press, pp. 110-12 (1987); Sayre et al., "Molecular Cloning and Expression of T11 cDNAs Reveals a Receptor- Like Structure on Human T lymphocytes", Proc. Natl.

Acad. Sci. USA, 84, pp. 2941-45 (1987)). The sequence of a human CD2 gene has been reported (Seed and Aruffo, "Molecular Cloning of the CD2 Antigen, the T-cell Erythrocyte Receptor, by a Rapid Immunoselection Procedure", Proc. Natl. Acad. Sci. USA, 84, pp. 3365-69 (1987); Sayre et al., supra (1987). Soluble CD2 polypeptides having an LFA-3 binding domain have been reported (PCT publ. WO 90/08187).

Monoclonal antibodies to CD2, for example TS2/18, T11 1 T11 2 T11 3 and to LFA-3, for example TS2/9, have also been reported (see, Hughes et al., "The Endothelial Cell as a Regulator of T-Cell Function", Immunol. Reviews, 117, pp. 85-102 (1990); Meuer, "An Alternative Pathway of T-Cell Activation:

A

Functional Role for the 50 kd T11 Sheep Erythrocyte Receptor Protein", Cell, 36, pp. 897-906 (1984); Sanchez-Madrid et al., "Three Distinct Antigens Associated with Human T-Lymphocyte-Mediated Cytolysis: 2 5 L FA 1 LFA-2, and LFA-3", Proc. Natl. Acad. Sci. USA, 79, pp. 7489-93 (1982)).

Suppression of the immune response to prevent graft rejection has previously been effected by drugs, such as prednisone, cyclosporine, azathioprine or 30 cyclophosphamide, which nonspecifically block cellmediated responses. Irradiation has also been used to destroy T and B lymphocytes that could react against the transplanted graft tissue. Immunosuppression with the above techniques, however, cannot produce antigenspecific tolerance and, therefore, greatly increases 5A Monoclonal Antibodies that Block E-Rosette Formation" -J Imunol., 126, pp. 2117-22 (1981); Brown et al., in Leukocte Typing III, ed. McMichael, Oxford University Press, pp. 110-12 (1987); -Sayre et al., "Molecular Cloning and Expression of T11 cDNAs Reveals a Receptor Like Structure on Human T lymphocytes", roc. Natl Acad. Sc. USA, 84, pp. 2941-45 (1987)). The sequence of a human CD2 gene has been reported (Seed and Aruffo, "Molecular Cloning of the CD2 Antigen, the T-cell Erythrocyte Receptor, by a Rapid Immunoselection Procedure", Proc. Natl. Acad. Sci. USA, 84, pp. 3365-69 (1987); Sayre et al., sua (1987). Soluble CD2 polypeptides having an LFA-3 binding domain have been reported (PCT publ. WO 90/08187).

Monoclonal antibodies to CD2, e.g, TS2/18, T11 1 T11 2 T11 3 and to LFA-3, TS2/9, have also been reported (see, Hughes et al., "The Endothelial Cell as a Regulator of T-Cell Function", Immunol. Reviews, 117, pp. 85-102 (1990); Meuer, "An 20 Alternative Pathway of T-Cell Activation: A Functional Rolefor the 50 kd T11 Sheep Erythrocyte Receptor Protein", Cell, 36, pp. 897-906 (1984); Sanchez-Madrid et al., "Three Distinct Antigens Associated with Human T-Lymphocyte-Mediated Cytolysis: LFA-1, LFA-2, and 25 LFA-3 Proc Natl. Acad. Sci. USA, 79, pp. 7489-93 (1982)); Bromberg et al., Translantaion 51, pp. 219- 225 (1991); EP 0 260 880 A2.

ft reeSuppression of the immune response to prevent graft rejection has previously been effected by drugs, such as prednisone, cyclosporine, azathioprine or cyclophosphamide, which nonspecifically block cell- S. mediated responses. Irradiation has also been used to destroy T and B lymphocytes that could react against the transplanted graft tissue Iunosuppression with the above techniques, however, cannot produce antigenspecific tolerance and, therefore, greatly increases 6 the patient's susceptibility to opportunistic infection. In addition, other detrimental side effects will occur with chronic use of the above immunosuppression techniques, For example, chronic cyclosporine treatment is associated with a high incidence of renal toxicity, hypertension and malignant neoplasm.

Cytotoxic T lymphocyte mediated x-sponses are controlled by cyclosporine or prednisone, but immune suppressive therapy is ineffectual for humoral rejection episodes. Currently, there is no therapeutic intervention for humoral rejection.

To date, therefore, conventional methods and therapeutic agents have not proved to be satisfactory for improving tolerance of xenografts or allografts.

Accordingly, the need still exists for a process which avoids the disadvantages of the conventional methods and agents while providing an effective method for decreasing the severity of rejection of graft tissue.

20 20 SUMMARY OF THE INVENTION The present invention generally solves many of the problems referred to above. It, for the first time, provides a method for improving tolerance of transplanted allograft tissue or xenograft tissue in a 25 mammal. The method of this invention comprises the steps of administering to a mammal, preferably a human, Sa graft tissue and an LFA-3 or CD2 binding protein.

The methods of the invention will preferably be used to improve tolerance of cardiac and renal xenografts and 30 allografts. The methods of this invention are superior to previously available therapies for improving graft tolerance for many reasons, including avoidance of undesirable side effects such as increased susceptibility to opportunistic infection, renal toxicity, hypertension and malignant neoplasm.

Disclosure of the Invention According to a first embodiment of this invention there is provided a method for improving tolerance of transplanted allograft tissue or xenograft tissue comprising the steps of administering to a human, the graft tissue and a monoclonal anti-LFA-3 antibody.

According to a second embodiment of this invention there is provided a method for improving tolerance of transplanted allograft tissue or xenograft tissue comprising the steps of administering to a human, the graft tissue and a soluble LFA-3 polypeptide linked to a human iminunoglobulin heavy chain hinge region and constant region, or portions thereof.

According to a third embodiment of this invention there is provided a method for improving tolerance of transplanted allograft or xenograft tissue in a human, comprising administering a monoclonal anti-LFA-3 antibody or a soluble protein that binds CD2 to a human in need of such method.

According to a fourth embodiment of this invention there is provided a method for improving tolerance of transplanted allograft tissue or xenograft tissue comprising the steps of administering to a human, the graft tissue and a soluble LFA-3 polypeptide.

Brief Description of the Drawings Figures 1 and 2 illustrate T cell dependent B cell activation assay results for two 20 baboons injected with an anti-LFA-3 monoclonal antibody (1E6) and one baboon injected with a non-specific isotype matched control monoclonal antibody (MOPC21).

9 9 *i

*I

[I:\DAYLB\LIBH]08724.doc:MCC 7A Immunoglobulin production as measured by OD units in an ELISA assay is reflected on the y axes. The number of days after the initial injection of anti-LFA-3 monoclonal antibody is illustrated on the x axes.

Detailed Description of the Invention Definitions As used herein, an "LFA-3 binding protein" is a protein comprising one or more polypeptides capable of binding to LFA-3. LFA-3 binding proteins include immunoglobulin light chains, immunoglobulin heavy chains and antigen-binding fragments thereof. The component polypeptides of an LFA-3 binding protein composed of more than one polypeptide may optionally be disulfide-bound or otherwise covalently crosslinked. Accordingly, LFA-3 binding proteins include intact immunoglobulins of types IgA, IgG, IgE, IgD, IgM (as well as subtypes thereof), wherein the light chains of the immunoglobulin may be of types kappa or lambda. Such binding proteins also include portions of intact immunoglobulins that retain LFA-3-binding specificity, for example, Fab fragments, Fab' fragments, F(ab')2 fragments, F(v) fragments, heavy chain monomers or dimers, light chain monomers of dimers, dimers consisting of one heavy and one light chain, and the like.

a o ff f o e e• f IN:\LIBUU]00844:RRB 8 Also contemplated within the term "LFA-3 binding protein" are soluble CD2 polypeptides and derivatives thereof, including fusions, that bind to LFA-3. As used herein, a "soluble CD2 polypeptide" is a CD2 polypeptide incapable of anchoring itself in a cell membrane. Such soluble polypeptides include, for example, CD2 polypeptides that lack a sufficient portion of their membrane-spanning domain to anchor the polypeptide or are modified such that the membranespanning domain is nonfunctional. Soluble CD2 polypeptides bind to a naturally occurring LFA-3 polypeptide and are encoded by a naturally occurring mammalian CD2 DNA sequence SEQ ID a DNA sequence degenerate to a naturally occurring CD2 DNA sequence or a DNA sequence that hybridizes to one of the foregoing DNA sequences under conditions equivalent to about 200C to 270C below Tm and 1 M sodium chloride. Such soluble CD2. polypeptides are well known. For example, several are described in 20 PCT WO 90/08187, which is herein incorporated by reference.

As used herein, a "CD2 binding protein" is a protein comprising one or more polypeptides capable of binding to CD2. CD2 binding proteins include 25 immunoglobulin light chains, immunoglobulin heavy chains and antigen-binding fragments thereof. The component polypeptides of a CD2 binding protein composed of more than one polypeptide may optionally be disulfide-bound or otherwise covalently crosslinked.

30 Accordingly, CD2 binding proteins include intact immunoglobulins of types IgA, IgG, IgE, IgD, IgM (as well as subtypes thereof), wherein the light chains of the immunoglobulin may be of types kappa or lambda.

Such binding proteins also include portions of intact immunoglobulins that retain CD2-binding specificity, 9 for example, Fab fragments, Fab' fragments, F(ab')2 fragments, F(v) fragments, heavy chain monomers or dimers, light chain monomers or dimers, dimers consisting of one heavy and one light chain, and the like.

Also contemplated within the term "CD2 binding protein" are soluble LFA-3 polypeptides or derivatives thereof, including fusions, that bind to- CD2. As defined herein, CD2 binding proteins include fusions of soluble LFA-3 polypeptides and immunoglobulin regions, such as LFA3TIP (described infra). As used herein, a "soluble LFA-3 polypeptide" is a LFA-3 polypeptide incapable of anchoring itself in a cell membrane. Such soluble polypeptides include, for example, LFA-3 polypeptides that lack a sufficient portion of their membrane-spanning domain to anchor the polypeptide or are modified such that the membranespanning domain is nonfunctional. Soluble LFA-3 polypeptides bind to a naturally occurring CD2 20 polypeptide and are encoded by a naturally occurring mammalian LFA-3 DNA sequence SEQ ID NO:1 or SEQ ID NO:3, a DNA sequence degenerate to a S* naturally occurring LFA-3 DNA sequence or a DNA sequence that hybridizes to one of the foregoing DNA 25 sequences under conditions equivalent to about 20 0 C to 27 0 C below Tm and 1 M sodium chloride. Such soluble LFA-3 polypeptides are well known. For example, several are described in United States patent 4,956,281, which is herein incorporated by reference.

30 As used herein, a "humanized recombinant antibody" is an antibody, produced by recombinant DNA technology, in which some or all of the amino acids of a human immunoglobulin light or heavy chain not required for antigen binding have been substituted for 10 the corresponding amino acids from a nonhuman mammalian immunoglobuli~ light or heavy chain.

As used herein, a "chimeric recombinant antibody" is an antibody produced by recombinant

DNA

technology, in which all or part of the hinge and constant regions of an immunoglobulin light chain, heavy chain or both, have been substituted for the corresponding regions from another immunoglobulin ~±ght chain or heavy chain.

As used herein, "improving tolerance" of transplanted graft tissue is decreasing the severity of or eliminating one or more of the general characteristics of graft rejection. Such characteristics evidence immune response directed against the graft (foreign) tissue and include, for example, progressive infiltration of mononuclear cells, such as lymphocytes, into the foreign tissue, production of lymphocytotoxic antibodies, cytolysis, necrosis, vasculitis, hemorrhage and fibrosis. Another 20 readily observable indication of improved tolerance will be prolonged survival of transplanted graft tissue in a recipient as compared to a non-immunosuppressed recipient (control).

Graft Tissue 25 The methods of this invention are useful in improving tolerance in mammals, including humans, of transplanted allograft tissue or xenograft tissue.

o00&, They comprise the steps of administering to the mammal a graft tissue and an LFA-3 or CD2 binding protein.

30 Such grafts include allografts and xenografts of tissues derived from sources including the heart, kidney, liver, pancreas, cornea, bone marrow, lung, skin and blood. Such tissues include portions of the organs mentioned above and subfractions of blood.

11 Preferably, the methods of this invention are used for cardiac allografts and xenografts, and renal allografts and xenografts. The methods of the invention can be practiced on any mammal, preferably humans.

In selecting graft tissue, a variety of factors should be considered. These include, for example, a minimization of genetic disparity to the extent possible, ABO blood group compatibility,

HLA

compatibility, the availability of donor tissue, the immune status of the patient and size of the donor organ. Specifically, in the case of cardiac and renal allografts or xenografts, the donor organ should be anatomically compatible and physiologically competent to support the organ function requirements of the recipient. Surgical protocols used for various graft transplants are well known.

While not wishing to be bound by theory, applicants believe that the LFA-3 and CD2 binding proteins used in the methods of this invention are 20 prophylactic and therapeutic for inducing tolerance of So the xenografts or allografts because they inhibit T cell activation. This inhibition typically occurs when the LFA-3 or CD2 binding protein inhibits the LFA-3/CD2 interaction. However, certain LFA-3 and CD2 binding proteins used in this invention may inhibit T cell activation without inhibiting the LFA-3/CD2 interaction.

Preferred LFA-3 and CD2 binding proteins for use in the methods of this invention are effective to 30 inhibit T cell activation.

The utility in the methods of this invention of specific LFA-3 or CD2 binding proteins may easily be determined by assaying their ability to inhibit the LFA-3/CD2 interaction, their ability to inhibit T cell activation or both.

12 The ability to inhibit the LFA-3/CD2 interaction may be assayed, for example, using a simple cell binding assay that permits visual (under magnification) evaluation of the ability of the putative inhibitor to inhibit the interaction between LFA-3 and CD2 on cells expressing these molecules.

Jurkat cells are preferred as the CD2 substrate and sheep red blood cells or human JY cells are preferred as the LFA-3+ substrate. The binding characteristics of binding proteins useful in this invention may be assayed in several known ways, such as by radiolabeling the binding protein with 35S or 1251) and then contacting the labeled binding protein with CD2+ or LFA-3 cells, as appropriate. Binding characteristics may also be assayed using an appropriate enzymatically labelled secondary antibody. Rosetting competition assays, such as those described in Seed et al., Proc.

Natl. Acad. Sci. USA, 84, pp. 3365-69 (1987) may also be used.

20 The ability of LFA-3 and CD2 binding proteins to inhibit T cell activation may be determined in any number of conventional T cell activation assays. These include, for example, assays which assess the ability of the binding protein to inhibit T cell proliferation 25 or cytokine secretion in response to mitogens or activating monoclonal antibodies directed to other cell surface proteins (see, Moingeon et al., "The Structural Biology of CD2", Immunoloqical Rev., 111, S: PP. 111-44 (1989)).

LFA-3 and CD2 Binding Proteins Many types of LFA-3 and CD2 binding proteins are useful in the methods of this invention, including monoclonal antibodies, recombinant antibodies, chimeric recombinant antibodies, humanized recombinant 13 antibodies, soluble LFA-3 and CD2 polypeptides and LFA-3 and CD2 mimetic agents, as well as derivatized fused to another polypeptide) or truncated forms of any of the foregoing.

A. Antibodies The LFA-3 and CD2 binding proteins useful in this invention-include monoclonal antibodies, recombinant antibodies, chimeric recombinant antibodies, humanized recombinant antibodies, and antigen binding portions thereof. Preferably, the antibodies are monoclonal antibodies.

It is more preferable to use a monoclonal anti-LFA-3 antibody produced by a hybridoma selected from the group of hybridomas having accession numbers ATCC HB 10693 (1E6), ATCC HB 10694 (HC-1B11), ATCC HB 10695 (7A6), and ATCC HB 10696 (8B8), or the monoclonal antibody known as TS2/9 (Sanchez-Madrid et al., "Three Distinct Antigens Associated With Human T-Lymphocyte- Mediated Cytolysis: LFA-1, LFA-2 and LFA-3", Proc.

Natl. Acad. Sci. USA., 79, pp. 7489-93 (1982)). Most preferably, the monoclonal anti-LFA-3 antibody is produced by the hybridoma having accession number ATCC HB 10693 (1E6) Among the anti-CD2 antibodies, preferable 25 monoclonal antibodies include monoclonal antibodies known as the T11 1 epitope antibodies, including TS2/18 (Sanchez-Madrid et al., supra, (1982)).

The technology for producing monoclonal antibodies is well known. Briefly, an immortal cell line (typically myeloma cells) is fused to lymphocytes (typically splenocytes) from a mammal immunized with a preparation comprising a given antigen, and the culture supernatants of the resulting hybridoma cells are screened for antibodies against the antigen. See 14 generally, Kohler et al., "Continuous Cultures Of Fused Cells Secreting Antibody Of Predefined Specificity", Nature, 256, pp. 495-97 (1975). Useful immunogens for the purpose of this invention include LFA-3-expressing or CD2-expressing cells, as well as cell tree preparations containing LFA-3, CD2, or counter receptor-binding fragments thereof CD2 fragments that bind to LFA-3 or LFA-3 fragments that bind to CD2). Also useful are derivatized forms of LFA-3, CD2 or portions thereof, such as fusion proteins consisting of a soluble LFA-3 polypeptide fused to at least portions of immunoglobulin hinge and constant domains LFA3TIP, described infra).

Immunization may be accomplished using standard procedures. The unit dose and immunization regimen depend on the species of mammal immunized, its immune status, the body weight of the mammal, etc.

Typically, the immunized mammals are bled and the serum from each blood sample is assayed for particular 20 antibodies using appropriate screening assays. For example, useful anti-LFA-3 and anti-CD2 antibodies may be identified by testing the ability of the immune serum to block sheep red blood cell rosetting of Jurkat S: cells, which results from the presence of LFA-3 and CD2 on the respective surfaces of these cells, screening for the ability to inhibit T cell activation in vitro .S or screening for both. The lymphocytes used in the production of hybridoma cells typically are isolated from immunized mammals whose sera have already tested 30 positive for the presence of the desired antibodies using such screening assays.

Typically, the immortal cell line a myeloma cell line) is derived from the same mammalian species as the lymphocytes. Preferred immortal cell lines are mouse myeloma cell lines that are sensitive 15 to culture medium containing hypoxanthine, aminopterin and thymidine ("HAT medium").

Typically, HAT-sensitive mouse myeloma cells are fused to mouse splenocytes using polyethylene glycol (PEG 3350). Hybridoma cells resulting from the fusion are then selected using HAT medium, which kills unfused and unproductively fused myeloma cells (unfused splenocytes die after several days because they are -not transformed). Hybridomas producing a desired antibody are detected by screening the hybridoma culture supernatants, for example, for the ability to bind to LFA-3 or CD2, or for their ability to block Jurkat cell adhesion to sheep red blood cells. Useful hybridomas may also be identified by screening for the ability to inhibit T cell activation. Subcloning of the hybridoma cultures by limiting dilution is typically performed to S-ensure monoclonality.

To produce anti-LFA-3 and anti-CD2 monoclonal antibodies, hybridoma cells that tested positive in 20 such screening assays are cultured in a nutrient medium under conditions and for a time sufficient to allow the hybridoma cells to secrete the monoclonal antibodies into the culture medium. Tissue culture techniques and culture media suitable for hybridoma cell culture are well known. The conditioned hybridoma culture supernatant may be collected and the desired antibodies optionally further purified by well known methods.

Alternatively, the desired antibody may be produced by injecting the hybridoma cells into the -30 peritoneal cavity of a Pristane-primed [2,6,10,14tetramethylpentadecane (Aldridge Chemical Co., Milwaukee, Wisconsin)] mouse. The hybridoma cells proliferate in the peritoneal cavity and secrete the antibody which accumulates in ascites fluid. The 16 antibody may be harvested by withdrawing the ascites fluid from the peritoneal cavity with a syringe.

LFA-3 and CD2 binding proteins useful in the present invention may also be recombinant antibodies produced by host cells transformed with DNA encoding immunoglobulin light and heavy chains of a desired antibody, or LFA-3 or CD2-binding portions thereof.

Recombinant antibodies may be produced by well known genetic engineering techniques. See, United States patent 4,816,397, which is incorporated herein by reference.

For example, recombinant antibodies may be produced by cloning cDNA or genomic DNA encoding the immunoglobulin light and heavy chains of the desired antibody from a hybridoma cell that produces an antibody useful in this invention. The cDNA or genomic DNA encoding those polypeptides is then inserted into expression vectors so that both DNA sequences are operatively linked to one or more transcriptional and 20 translational expression control sequences. The :'expression vector and expression control sequences are chosen to be compatible with the expression host cell used. Typically, both DNA sequences are inserted into the same expression vector, although the two DNA sequences may also be inserted into different expression vectors.

Prokaryotic or eukaryotic host cells may be used as expression hosts. Expression in eukaryotic host cells is preferred because such cells are more 30 likely than prokaryotic cells to assemble and secrete a properly folded and immunologically active antibody.

However, any antibody produced that is inactive due to improper folding may be renaturable according to well known methods (Kim and Baldwin, "Specific Intermediates in the Folding Reactions of Small Proteins and the 17 Mechanism of Protein Folding", Ann. Rev. Biochem., 51, pp. 459-89 (1982)). It is possible that the host cells will produce portions of intact antibodies useful in this invention, such as light chain dimers or heavy chain dimers.

It will be understood that variations on the above procedure are useful in the present invention.

For example, it may alternatively be desired to transform a host cell with DNA encoding either the light chain or the heavy chain (but not both) of an anti-LFA-3 or anti-CD2 antibody. Recombinant

DNA

technology may also be used to remove some or all of the DNA encoding either or both of the light and heavy chains that is not necessary for LFA-3 or CD2 counter receptor binding. The molecules expressed from such truncated DNA molecules are useful in the methods of S. this invention. In addition, bifunctional antibodies may be produced in which one heavy and one light chain are specific for LFA-3 or CD2 and the other heavy and 20 light chain are specific for an antigen other than LFA-3 or CD2, or for another epitope of LFA-3 or CD2.

Chimeric recombinant antibodies may be produced by transforming a host cell with a suitable expression vector comprising DNA encoding the desired immunoglobulin light and heavy chains in which all or some of the DNA encoding the hinge and constant regions "of the heavy and/or the light chain have been substituted with DNA from the corresponding region of an immunoglobulin light or heavy chain of a different 30 species. When the original recombinant antibody is nonhuman and the anti-LFA-3 or anti-CD2 antibody will be administered to a human, substitution of corresponding human sequences is preferred. An exemplary chimeric recombinant antibody has mouse variable regions and human hinge and constant regions.

18 See generally, United States patent 4,816,397 and Morrison et al., "Chimeric Human Antibody Molecules: Mouse Antigen-Binding Domains With Human Constant Region Domains", Proc. Natl. Acad. Sci. USA, 81, pp. 6851-55 (1984).

Humanized recombinant anti-LFA-3 or anti-cD2 antibodies may be produced by transforming a host cell with a suitable expression vector comprising

DNA

encoding the desired nonhuman immunoglobulin light and heavy chains in which all or some of the DNA encoding amino acids not involved in antigen binding have been substituted with DNA from the corresponding region of a desired human immunoglobulin light or heavy chain. See generally, Jones et al., "Replacing The Complementarity-Determining Regions In A Human Antibody With Those From A Mouse", Nature, 321, pp. 522-25 (1986) and European patent publication 0 239 400.

Anti-LFA-3 and anti-CD2 antibodies that are not intact are also useful in this invention, and may 20 be derived from any of the antibodies described above.

For example, antigen-binding fragments, as well as full-length monomeric, dimeric or trimeric polypeptides derived from the above-described antibodies are themselves useful. Useful binding proteins of this type include Fab fragments, Fab' fragments, F(ab') 2 fragments, F(v) fragments, heavy chain monomers or dimers, light chain monomers or dimers, dimers consisting of one heavy and one light chain, and the like.

Antibody fragments may also be produced by chemical methods, by cleaving an intact antibody with a protease, such as pepsin or papain, and optionally treating the cleaved product with a reducing agent. Alternatively, useful fragments may be produced by using host cells transformed with truncated heavy 19 and/or light chain genes. Heavy and light chain monomers may be produced by treating an intact antibody with a reducing agent, such as dithiothreitol, followed by purification to separate the chains. Heavy and light chain monomers may also be produced by host cells transformed with DNA encoding either the desired heavy chain or light chain, but not both. See, Ward et al., "Binding Activities Of A Repertoire Of Single Immunoglobulin Variable Domains Secreted From Escherichia coli", Nature, 341, pp. 544-46 (1989); Sastry et al., "Cloning Of The Immunological Repertoire in Escherichia coli For Generation Of Monoclonal Catalytic Antibodies: Construction Of A Heavy Chain Variable Region-Specific cDNA Library", Proc. Natl Acad. Sci. USA, 86, pp. 5728-32 (1989).

B. Soluble CD2 and LFA-3 Polypeptides The LFA-3 and CD2 binding proteins useful in the methods of the present invention include soluble CD2 and LFA-3 polypeptides. Soluble LFA-3 polypeptides are preferred.

Soluble LFA-3 polypeptides may be derived from the transmembrane form of LFA-3, particularly the extracellular domain AAl-AA87 of SEQ ID NO:2).

Such polypeptides are described in United States patent *25 4,956,281 and co-pending, commonly assigned United States patent applications 07/667,971 and 07/770,967, which are herein incorporated by reference. Preferred *soluble LFA-3 polypeptides include polypeptides consisting of AAI-AA 92 of SEQ ID NO:2, AAI-AA80 of SEQ ID NO:2, AA50-AA 65 of SEQ ID NO:2 and AA20-AA80 of SEQ ID NO:2. A bacteriophage comprising a DNA sequence encoding SEQ ID NO:2 SEQ ID NO:1) is deposited with American Type Culture Collection, Rockville, Maryland, under the accession number ATCC 75107.

20 Soluble LFA-3 polypeptides may also be derived from the PI-linked form of LFA-3, such as those described in PCT patent application WO 90/02181.

A

vector comprising a DNA sequence encoding PI-linked LFA-3 SEQ ID NO:3) is deposited with American Type Culture Collection, Rockville, Maryland, under the accession number ATCC 68788. Since the PI-linked form of LFA-3 and the transmembrane form of LFA-3 have identical amino acid sequences through the entire extracellular domain, the preferred soluble LFA-3 polypeptides derived from PI-linked LFA-3 are the same as those derived from the transmembrane form of LFA-3.

Soluble CD2 polypeptides may be derived from full length CD2, particularly the extracellular domain

AA-AA

185 of SEQ ID NO:6). Such polypeptides may comprise all or part of the extracellular domain of CD2. Suitable soluble CD2 polypeptides are described in PCT WO 90/08187, which is herein incorporated by reference.

20 The production of the soluble polypeptides useful in this invention may be achieved by a variety of methods known in the art. For example, the polypeptides may be derived from intact transmembrane LFA-3 or CD2 molecules or an intact PI-linked LFA-3 molecule by proteolysis using specific endopeptidases in combination with exopeptidases, Edman degradation, or both. The intact LFA-3 molecule or the intact CD2 molecule, in turn, may be purified from its natural source using conventional methods. Alternatively, the 30 intact LFA-3 or CD2 may be produced by known recombinant DNA techniques using cDNAs (see,

U.S.

Patent 4,956,281 to Wallner et al.; Aruffo and Seed, Proc. Natl. Acad. Sci. USA, 84, pp. 2941-45 (1987); Sayre et al., Proc. Natl. Acad. Sci. USA, 84, pp. 2941-45 (1987)).

21 Preferably, the soluble polypeptides useful in the present invention are produced directly, thus eliminating the need for obtaining an entire LFA-3 molecule or an entire CD2 molecule as a starting material. This may be achieved by conventional chemical synthesis techniques or by well-known recombinant DNA techniques wherein only those DNA sequences which encode the desired polypeptides are expressed in transformed hosts. For example a DNA sequence which encodes the desired soluble LFA-3 polypeptide or soluble CD2 polypeptide may be synthesized by chemical means using an oligonucleotide synthesizer. Such oligonucleotides are designed based on the amino acid sequence of the desired soluble LFA-3 polypeptide or soluble CD2 polypeptide. Specific

DNA

sequences coding for the desired polypeptide also can be derived from the full length DNA sequence by isolation of specific restriction endonuclease fragments or by PCR synthesis of the desired region.

20 The soluble LFA-3 and CD2 polypeptides may be isolated from the fermentation or culture of transfected host cells and purified using any of a variety of conventional methods. One of skill in the art may select the most appropriate isolation and purification techniques.

While recombinant DNA techniques are the preferred method of producing useful soluble CD2 polypeptides or soluble LFA-3 polypeptides having a sequence of more than 20 amino acids, shorter CD2 or 30 LFA-3 polypeptides having less than about 20 amino acids are preferably produced by conventional chemical synthesis techniques. Synthetically produced polypeptides useful in this invention can advantageously be produced in extremely high yields and can be easily purified.

22 C. LFA-3 And CD2 Mimetic Agents Among the LFA-3 and CD2 binding proteins useful in the methods of this invention are LFA-3 and CD2 mimetic agents. These agents are peptides, semi-peptidic compounds or non-peptidic compounds which bind to CD2 (LFA-3 mimetic) or to LFA-3 (CD2 mimetic) and inhibit the CD2/LFA-3 interaction, inhibit T cell activation or both.

Such mimetic agents may be produced by synthesizing a plurality of peptides 5-20 amino acids in length), semi-peptidic compounds or nonpeptidic, organic compounds, and then screening those compounds for their ability to inhibit the CD2/LFA-3 interaction or for their ability to inhibit T cell activation or both. See generally United States patent 4,833,092; Scott and Smith, "Searching for Peptide Ligands with an Epitope Library", Science, 249, pp. 386-90 (1990); and Devlin et al., "Random Peptide Libraries: A Source of Specific Protein Binding 20 Molecules", Science, 249, pp. 404-07 (1990), which are a. herein incorporated by reference.

D. Derivatized LFA-3 And CD2 Binding Proteins Also useful in the methods of this invention 25 are derivatized forms, including fusions or hybrids, of the foregoing LFA-3 and CD2 binding proteins in which, for example, any of the LFA-3 or CD2 binding proteins described herein are functionally linked (by chemical coupling, genetic fusion or otherwise) to one or more of the same or different LFA-3 and CD2 binding proteins, to pharmaceutical agents, or to both.

One type of derivatized binding protein is produced by crosslinking two or more LFA-3 or CD2 binding proteins (of the same type or of different 23 types). Suitable crosslinkers include those that are heterobifunctional, having two distinctly reactive groups separated by an appropriate spacer m-maleimidobenzoyl-N-hydroxysuccinimide ester) or homobifunctional disuccinimidyl suberate). Such linkers are available from Pierce Chemical Company, Rockford, Illinois.

Another possibility for cross-linking takes advantage of the PI linkage signal sequence in PIlinked LFA-3, or fragments thereof. Specifically,

DNA

encoding the PI-linkage signal sequence

AA

162 AA212 of SEQ ID NO:4) is ligated downstream of DNA encoding a desired polypeptide, preferably a soluble LFA-3 polypeptide. If this construct is expressed in an appropriate eukaryotic cell, the cell will recognize the PI linkage signal sequence and will covalently link PI to the polypeptide. The hydrophobic property of the 6 P" PI may then be exploited to form micellar aggregates of the polypeptides.

20 Also useful are LFA-3 and CD2 binding proteins linked to one or more pharmaceutical agents a fusion or hybrid protein). Useful pharmaceutical agents include biologically active peptides, polypeptides and proteins, such as antibodies specific for a polypeptide other than LFA-3 or CD2.

Other useful pharmaceutical agents include immunosuppressants, for example, cyclosporine

A,

prednisone, FK506, methotrexate, steroids, and retinoids.

30 Preferred derivatized binding proteins include recombinantly produced polypeptides in which a soluble LFA-3 polypeptide, soluble CD2 polypeptide, or a peptidyl CD2 or peptidyl LFA-3 mimetic agent is fused to all or part of an immunoglobulin heavy chain hinge region and all or part of an immunoglobulin heavy chain 24 constant region. Such fusion proteins are expected to exhibit prolonged serum half-lives and to facilitate binding protein dimerization.

Preferred polypeptides for preparing such fusion proteins are soluble LFA-3 polypeptides, most preferably a soluble LFA-3 polypeptide selected from the group consisting of AAI-AA 92 of SEQ ID NO:2, AAl-AA 80 of SEQ ID NO:2, AA50-AA6 of SEQ ID NO:2 and AA 20

-AA

80 of SEQ ID NO:2.

A bacteriophage comprising a DNA sequence encoding SEQ ID NO:2 SEQ ID NO:1) is deposited with the American Type Culture Collection, Rockville, Maryland, under the accession number ATCC 75107.

The most preferred fusion proteins of this type contain the amino terminal 92 amino acids of mature LFA-3, the C-terminal 10 amino acids of a human IgG 1 hinge region containing the two cysteine residues thought to participate in interchain disulfide bonding, and the CH 2 and CH 3 regions of a human IgG 1 heavy chain 20 constant domain SEQ ID NO:8). This fusion protein is referred to herein as "LFA3TIP." A plasmid, pSAB152, encoding an exemplary LFA3TIP is deposited with American Type Culture Collection, Rockville, Maryland, under the accession number ATCC 68720. The DNA sequence of the pSAB152 insert is SEQ ID NO:7.

One way of producing LFA3TIP for use in the S. methods of this invention is described in co-pending, commonly assigned United States patent application 07/770,967. Generally, conditioned culture medium of 30 COS7 cells transfected with pSAB152 was concentrated using an AMICON S1Y30 spiral cartridge system

(AMICON,

Danvers, Massachusetts) and subjected to Protein

A-

Sepharose 4B (Sigma, St. Louis, Missouri) chromatography. The bound proteins were eluted and 25 subjected to Superose-12 (Pharmacia/LKB, Piscataway, New Jersey) gel filtration chromatography.

Superose-12 fractions containing LFA3TIP with the least amount of contaminating proteins, as determined on SDS-PAGE gels and by Western blot analysis, (see, Towbin et al., Proc. Natl. Acad.

Sci. USA, 74, pp. 4350-54 (1979); Antibodies:

A

Laboratory Manual, pp. 474-510 (Cold Spring Harbor Laboratory (1988)), were pooled and concentrated in a YM30 Centricon (AMICON). LFA3TIP was detected on Western blots using a rabbit anti-LFA-3 polyclonal antiserum, followed by detectably labeled goat antirabbit IgG. The purified LFA3TIP of COS7 cells was a dimer of two monomeric LFA-3-Ig fusion proteins, connected by disulfide bonds.

Pharmaceutical Compositions And Methods According To This Invention The methods according to this invention improve tolerance of transplanted allograft tissue or 20 xenograft tissue by administering to a mammal the graft tissue and one or more LFA-3 or CD2 binding proteins, including derivatized forms thereof. The LFA-3 or CD2 binding proteins may alternatively be administered as part of a pharmaceutical composition.

Useful pharmaceutical compositions will comprise one or more LFA-3 or CD2 binding proteins, including derivatized forms thereof, typically in a pharmaceutically acceptable carrier. By "pharmaceutically acceptable carrier" is meant a 30 carrier that does not cause an allergic reaction or other untoward effect in patients to whom it is administered.

Suitable pharmaceutically acceptable carriers include, for example, one or more of water, saline, phosphate buffered saline, dextrose, glycerol, ethanol 26 and the like, as well as combinations thereof.

Pharmaceutically acceptable carriers may further comprise minor amounts of auxiliary substances such as wetting or emulsifying agents, preservatives or buffers, which enhance the shelf life or effectiveness of the LFA-3 or CD2 binding protein.

The LFA-3 or CD2 binding proteins or compositions useful in this invention wfll preferably be administered in an "effective amount," meaning an amount capable of improving tolerance to an allograft or xenograft as defined herein.

It will be apparent to those of skill in the art that the effective amount of LFA-3 or CD2 binding protein will depend, inter alia, upon the administration schedule, the unit dose administered, whether the LFA-3 or CD2 binding protein is administered in combination with other therapeutic *agents, the immune status and health of the patient, the therapeutic or prophylactic activity of the S. 20 particular LFA-3 or CD2 binding protein administered and its serum half-life.

The pharmaceutical compositions may further be used in conjunction with general immunosuppressive agents. These include, for example, cyclosporine, azathioprine and steroids, such as Depo-Medrol (methylprednisolone acetate), Solumederol (methylprednisolone sodium succinate), and prednisone, administered in amounts effective to suppress immune :response in the mammal being treated. For example, 30 cyclosporine may be administered at 2-25 mg/kg/day p.o.

starting the day before surgery, azathioprine may be administered at 50-200 mg/day, Solumederol may be administered at 125 mg.i.v. at the time of transplantation and on the first post-operative day, prednisone may be administered at 1 mg/kg/day p.o.

27 starting on the second post-operative day or Depo-Medrol may be administered at 0.8 mg/kg/day i.m.

starting on the second post-operative day. The above dosages will, of course, be varied by the practitioner depending upon factors well known to those of skill in the art. In general, when used in conjunction with an LFA-3 or CD2 binding protein, it will be desired to use the lowest possible-effective concentration of such immunosuppressive agents.

The pharmaceutical compositions may further comprise other therapeutic or prophylactic agents. The LFA-3 or CD2 binding protein and the other active agent may be in the form of a single conjugated molecule.

Conjugation of the two components may be achieved by standard cross-linking techniques well known in the art. A single molecule may also take the form of a recombinant fusion protein.

The additional immunosuppressive, therapeutic or prophylactic agents may be administered in single dosage form with the LFA-3 or CD2 binding protein, in a multiple dosage form separately from the LFA-3 or CD2 .binding protein, but contemporaneously, or in a multiple dosage form wherein the components are administered separately but sequentially. Such combination therapies may advantageously utilize lower dosages of the immunosuppressive, therapeutic or prophylactic agents.

The pharmaceutical compositions or LFA-3 or CD2 binding proteins may be in a variety of forms.

30 These include, for example, solid, semi-solid and liquid dosage forms, such as tablets, pills, powders, liquid solutions, dispersions or suspensions, liposomes, suppositories, injectable and infusible solutions. The preferred form depends on the intended mode of administration and therapeutic application.

28 The preferred form is injectable or infusible solutions.

Typically, the LFA-3 or CD2 binding protein will be suspended in a sterile saline solution for therapeutic uses. The pharmaceutical compositions may alternatively be formulated to control release of the active ingredients or to prolong their presence in a recipient's system. Numerous suitable drug delivery systems are known and include, hydrogels, hydroxymethylcellulose, microcapsules, liposomes, microemulsions, microspheres, and the like.

In accordance with this invention, a mammal that is to receive transplanted graft tissue and an LFA-3 binding protein is administered a dose between about 0.01 and about 10 mg LFA-3 binding protein per kg body weight, more preferably between about 0.1 and about 5 mg LFA-3 binding protein per kg body weight, and most preferably between about 0.1 and about 2 mg LFA-3 binding protein per kg body weight.

20 A mammal that is to receive transplanted graft tissue and a CD2 binding protein is administered a dose between about 0.01 and about 10 mg CD2 binding protein per kg body weight, more preferably between about 0.01 and about 2 mg CD2 binding protein per kg 25 body weight, and most preferably between about 0.01 and about 1 mg CD2 binding protein per kg body weight.

The LFA-3 or CD2 binding protein or composition should be administered about once per day until, within the judgment of the practitioner, the 30 danger of rejection of the allograft or xenograft .tissue has diminished. The length of administration of the LFA-3 or CD2 binding protein or composition is dependent upon the mammal's acceptance of the graft tissue. General clinical indications of rejection will vary with the particular organ transplanted. However, 29 fever, malaise and organ dysfunction are typical clinical indications of rejection. Symptoms of organ dysfunction depend upon the organ transplanted, but are characterized by well known and recognized indicia to those of skill in the art.

The success of the treatment may be measured by a variety of methods including biopsies, such as incisional myocardial biopsy or percutaneous endomyocardial biopsy to determine the extent of lymphocyte infiltration, blood assays to determine the extent of lymphocytotoxic antibody production or a mixed lymphocyte reaction (see, Krensky et al., J. Immunol., 131, pp. 611-16 (1983); Bradley, "Mixed Lymphocyte Responses", in Selected Methods in Cellular Immunology (Mishell and Shiigi, eds.), pp. 162-64

(W.H.

Freeman and Co., San Francisco 1980)). In the case of renal transplants, biopsies can be taken to determine the extent of mononuclear cell infiltration and proliferation, or necrosis of the arterial endothelium and media in the graft tissue. (Cosimi et al., J. Immunol., 144, pp. 4604-12 (1990)).

The method of the present invention, in a preferred embodiment for allograft tissue, comprises administering the LFA-3 or CD2 binding protein once per 25 day for two consecutive days before the transplant and once per day for one to ten consecutive days after the transplant. More preferably, the LFA-3 or CD2 binding protein is administered once per day for two consecutive days before the transplant and once per day 30 for two consecutive days after the transplant.

The method of the present invention, in a preferred embodiment for xenograft tissue, comprises administering, before the transplant, an LFA-3 or CD2 binding protein contemporaneously with tissue from the xenograft source. As used herein, "contemporaneously" 30 when referring to the administration of tissue from a xenograft source (other than the graft tissue) and an LFA-3 or CD2 binding protein, will mean that their administration occurs near enough in time to allow the binding protein to bind to the tissue from the xenograft source at an effective level to inhibit a significant immune response. Preferably, the binding protein is bound to the tissue from the xenograft source at saturating levels. In a preferred embodiment of this invention, administration of one occurs within approximately zero to six hours of the other. Most preferably, the tissue from the xenograft source and the LFA-3 or CD2 binding protein are administered within approximately zero to one hour of each other.

Either may be administered first. It is preferable, however, that the binding protein be administered prior to tissue from the xenograft source.

In an alternate embodiment of the present invention, the contemporaneous administration is 20 followed by the administration of LFA-3 or CD2 binding protein before the transplant.

More preferably, the LFA-3 or CD2 binding protein is administered before the xenograft transplant once per day for two consecutive days, then 25 contemporaneously with tissue from the xenograft source once per day for one day, and then once per day for one to ten consecutive days. If the xenograft source species and recipient species are unusually discordant, it may be necessary to administer the LFA-3 or CD2 30 binding protein contemporaneously with tissue from the xenograft source once per day for two consecutive days according to the above schedules. In a preferred embodiment, the binding protein is administered once per day for five to ten consecutive days after the contemporaneous administration and before the 31 transplant according to the above schedules. Most preferably, the contemporaneous administration of the LFA-3 or CD2 binding protein and tissue from the xenograft source is simultaneous.

Although not wishing to be bound by theory, applicants administer tissue from the xenograft source to the mammal contemporaneously with LFA-3 or CD2 binding protein with the intent of inhibiting the development of a population of activated cells specifically reactive against that tissue. The contemporaneous administration of LFA-3 or CD2 binding proteins induces tolerance to the specific subset of antigens carried by cells from the specific xenograft source. Accordingly, it will be understood that any tissue from the xenograft source may be appropriate, however blood cells from the xenograft source are preferred. Such tissue should be administered in an amount sufficient to elicit an immune response. The preferred method of administration of tissue from the 20 xenograft source is intravenous. The administration of between about 1 x 10 6 to about 1 x 108 whole blood cells most preferably will serve as the tissue from the xenograft source. It will be recognized, however, that lower or higher dosages and other administration 25 schedules may be employed.

The LFA-3 or CD2 binding protein or pharmaceutical composition may be administered intravenously, intramuscularly, subcutaneously, intra-articularly, intrathecally, periostally, orally, 30 topically or by inhalation. Ordinarily, intravenous or intramuscular administration will be preferred, however, more localized administrations in the area of transplantation may be more desirable in some cases due to the wide range of cells in the body that express LFA-3.

32 In a preferred embodiment of the method of the present invention, the graft tissue is perfused with an effective amount of LFA-3 or CD2 binding protein before implantation into the mammal. Most preferably, the graft tissue is perfused with enough LFA-3 or CD2 binding protein to saturate all CD2 or LFA-3 sites on the graft tissue before implantation into the mammal.

In order that this invention may be better understood, the following examples are set forth.

These examples are for purposes of illustration only, and are not to be construed as limiting the scope of the invention in any manner.

EXAMPLES

Example 1 Purification Of Anti-LFA-3 Monoclonal Antibody 1E6 and Monoclonal Antibody MOPC21 1E6 hybridoma cells (ATCC HB 10693) were grown in RPMI 1640 medium supplemented with 2% fetal 20 calf serum, 150 pg/ml streptomycin and 50 pg/ml gentamicin (GIBCO Life Technologies, Gaithersburg, Maryland) in three 40 liter stirred glass vessels (Bellco, 196536000) at 37 0 C for 7 10 days. The conditioned media was pooled and collected into 100 liter carboys (NALGENE). Sodium azide was added to make the pooled suspension 0.02% final concentration.

The cell debris was removed through a 5 p filter cartridge (Polygard, #CN5001E06, Millipore, Bedford, Massachusetts) followed by a 0.3 p filter cartridge (Polygard, #CN0301E06, Millipore, Bedford, Massachusetts) at room temperature. The clarified supernatant was concentrated 50 to 100 fold using a S10 spiral filter cartridge (AMICON, Danvers, Massachusetts) at 4 0 C. The concentrate from 50 liters 33 of conditioned media was diluted with two volumes of equilibration buffer (3 M glycine, 1.5 M sodium chloride, pH 8.9) and passed through 90 ml of Protein A-Sepharose (Schleicher and Schuell, Keene, New Hampshire) overnight by gravity at 4 0

C.

The column was washed with equilibration buffer and the bound proteins were subsequently eluted with 100 mM sodium citrate, pH 3.0. The eluted fractions were collected into 1/10 fraction volume of 1 M HEPES, pH 7.8. A280 readings of the fractions were taken and the fractions containing the eluted protein were pooled and stored at -70 0 C. Protein A-purified 1E6 was prepared from a total of about 200 liters of conditioned media. The various pools were thawed, combined and concentrated to about 10 mg/ml protein in a 2 liter Amicon stirred cell using a YM30 filter (AMICON, Danvers, Massachusetts). The concentrated material was divided into five 100 ml aliquots. Each aliquot was passed through a 1 liter Superose-6 gel 20 filtration column (Pharmacia, Piscataway, New Jersey) developed in phosphate buffered saline at room temperature. The peak fractions containing 1E6 were pooled and stored at -70 0 C. When all the material was processed, the pools were thawed, combined and adjusted 9 25 to 2-3 mg/ml protein with phosphate buffered saline.

The final material was divided into 15 ml aliquots and stored at -70 0 C until use.

MOPC21 was purified from ascites purchased from the Sigma Chemical Corporation (St. Louis, 30 Missouri) by diluting the ascites into the "Protein A loading buffer" of 3 M glycine, 1.5 M sodium chloride, pH 8.9, and passing it over 25 ml of Protein

A-

Sepharose (Schleicher and Schuell, Keene, New Hampshire) at room temperature. The column was washed with the loading buffer until the optical density at 34 280 nm returned to a baseline level. The bound IgG was eluted with 50 mM sodium acetate, pH 3.0, at room temperature and dialyzed overnight against 50 volumes of phosphate buffered saline at 40C. After dialysis, the MOPC21 was passed through a 1 liter Superose-6 gel filtration column (Pharmacia, Piscataway, New Jersey) developed in phosphate buffered saline at room temperature. The peak fractions containing MOPC21, were pooled, adjusted with phosphate buffered saline to a final concentration of 2 mg/ml protein and stored in mg aliquots at -70 0 C until use. All preparations contained less than 10 units/ml endotoxin as determined using the commercially available kit Chromogenic

LAL

(Whittaker M.A. Bioproducts, Walkersville, Maryland).

Except as otherwise noted, all purification steps were performed at room temperature.

Example 2 Effect Of Administration Of Anti-LFA-3 Monoclonal Antibody 1E6 On Lymphocyte Function 20 A. Administration And Sampling Protocols Two outbred, adult baboons A and B (Papio anubis) were given bolus injections of 1.45 mg/kg of the purified anti-LFA-3 monoclonal antibody 1E6, i.v., by portacatheter once daily for five consecutive days.

25 Baboon A weighed 12 kg. Baboon B weighed 9.5 kg. As a control, another adult baboon C, 9.4 kg, was injected with equal amounts of the non-specific, isotype-matched mouse monoclonal antibody MOPC21 (Sigma Chemical Corp., :St. Louis, Missouri). Blood was drawn from the baboons once or twice before the first injection of antibody and then, daily for five days, four hours after each injection. Blood was also drawn on day 8, day 11 and day 14, where day 1 is the day of the first injection.

This administration and sampling protocol was used for 35 all of the assays described in this example, unless otherwise stated.

B. Toxicology Study with Anti-LFA-3 Monoclonal Antibody 1E6 The general toxicity of anti-LFA-3 monoclonal antibody 1E6 and the potential effect on the physical condition, hematology and blood chemistry of baboons was evaluated. The general physical condition of the baboons remained unchanged throughout the study. No obvious or immediate side effects could be observed.

Hematology and blood chemistries generally remained normal. In particular, Na+, C1-, K creatine, blood urea nitrogen and liver enzymes AST and ALT levels all remained with normal limits. In addition, blood cell counts, including hematocrit, white blood cells, lymphocytes, monocytes, segmented neutrophils and eosinophils, generally stayed within normal ranges.

However, baboon B showed a substantial decrease in segmented neutrophils after day five.

20 C. Serum Levels of Anti-LFA-3 Monoclonal Antibody 1E6 and Control MOPC21 Serum was prepared from blood drawn four to* hours after antibody injection. For the baboons injected with 1E6 (baboons A and additional serum was collected at the 24 hour time point, just before the antibody injections on days one to five. Serum was also collected on days 8, 11 and 14. Serum levels of MOPC21 and 1E6 were determined by measurement of mouse IgG levels with an ELISA using microtiter plates coated with goat anti-mouse IgG (Jackson Immunoresearch, Malvern, Pennsylvania). These ELISAs were standardized using MOPC21 and 1E6 purified as described in Example 1. Serum levels of 1E6 capable of binding to LFA-3 "active" 1E6) were measured with an ELISA 36 using microtiter plates coated with a soluble LFA-3 polypeptide consisting of AAI-AA184 of LFA-3 (see U.S.

patent 4,956,281, which is herein incorporated by reference). This ELISA was also standardized with 1E6 purified as described in Example 1. In all of the above ELISA assays, binding of 1E6 or MOPC21 to microtiter plates was detected using a second goat 1 anti-mouse antibody that was labelled with-RAkaline phosphatase (Jackson Immunoresearch, Malvern, Pennsylvania). The bound immunoglobulin was quantified by the colorimetric conversion of the alkaline phosphatase substrate pNPP to its colored product using a Thermomax (Molecular Devices, Palo Alto, California).

The ELISA reader was at a wavelength of 405 nm. (Data not shown.) Serum levels of 1E6 and MOPC21 peaked between day four and day five (about 40-80 g/ml antibody) and returned to pre-injection levels between day eight and day eleven. Serum levels of 1E6, 24 hours after 20 injection, consistently decreased between 50% and of the level at four hours after injection for serum collected on days 1-5. In comparison, MOPC21 levels decreased only between 10% and 20% after 24 hours. The percentage of active 1E6 in serum varied between and 70%. 1E6 serum levels were higher in baboon B as compared to baboon A (9.5 kg compared to 12 kg body weight), possibly as a result of different tissue space distribution.

The titer of anti-1E6 antibodies in the 30 treated baboon serum was determined by ELISA. Purified 1E6 was coupled to microtiter plates and serum from each bleed was assayed at increasing dilutions. (Data not shown.) In both 1E6 injected baboons A and B, anti-1E6 antibodies were detected after the injection 37 as early as day eleven. Anti-MOPC21 titers were detected using anti-mouse IgG coated assay plates and showed the same kinetics as anti-1E6. (Data not shown.) D. T cell Activation Assays In Vitro To determine the effect of 1E6 injections on T cell activation in vitro, peripheral blood lymphocytes were isolated from antibody-injected baboons and assayed for T cell dependent B cell activation and for T cell proliferation in response to phytohemagglutinin or activating anti-CD2 monoclonal antibodies. For each of these assays, peripheral blood lymphocytes were isolated on Ficoll-Hypaque (Pharmacia, Piscataway, New Jersey), according to the manufacturer's suggested protocol. Peripheral blood lymphocytes were stored overnight in tissue culture medium containing 10% fetal calf serum at room temperature prior to each assay.

1. T cell Dependent B-Cell Activation Assay 20 The T cell dependent B cell activation to immunoglobulin secretion can be blocked by anti-LFA-3 antibodies (MOPC21 is used as a control).

Peripheral blood mononuclear cells were purified from whole blood on Ficoll Hypaque density 25 medium (Pharmacia, Piscataway, New Jersey), according to the manufacturer's instructions. Adherent macrophages were removed by incubating the mononuclear S. cells on plastic dishes for 45 minutes at 370C. The nonadherent lymphocytes were washed in a 30 physiologically compatible culture medium (RPMI 1640, GIBCO Life Technologies, Gaithersburg, Maryland), determined to contain minimal macrophages by FACS analysis on a FACStar (Becton Dickinson Corporation, 38 Mountainview, California) using fluorescently labelled antibodies specific for macrophage/monocyte cell surface antigens and cultured in 96-well round bottom plates (RPMI 1640 supplemented with 10% fetal calf serum, 2 mM glutamine, 5 x 10-5 M B-mercaptoethanol and nonessential amino acids (GIBCO Life Technologies, Gaithersburg, Maryland)).

In this culture, T cells activate B cells to secrete immunoglobulin. The B cells are not activated in the absence of T cells. The immunoglobulin secreted into the culture medium was measured by sampling culture medium on day seven and day twelve after the initiation of the culture. The supernatant (cell free) samples were analyzed for baboon immunoglobulin using an ELISA in which the assay plates were coated with goat anti-human immunoglobulin (Jackson Immunoresearch, Malvern, Pennsylvania), which also recognizes baboon immunoglobulin, but does not bind to immunoglobulin present in the fetal calf serum or to mouse 20 immunoglobulins. The immunoglobulins from the culture supernatants that were bound to the goat anti-human immunoglobulin-coated plates were detected using a second goat anti-human immunoglobulin reagent to which an enzyme, alkaline phosphatase, had been coupled (Jackson Immunoresearch, Malvern, Pennsylvania). The bound immunoglobulin was quantified by the colorimetric conversion of the alkaline phosphatase substrate pNPP (para-nitrophenylphosphate) to its colored product.

Substrate conversion was measured in a Thermomax 30 (Molecular Devices, Palo Alto, California) ELISA reader at a wavelength of 405 nm.

S* The results of these experiments are shown in Figures 1 and 2. Figure 1 displays relative absorbance units at 405 nm from the ELISA assay for assays performed on baboon B (1E6) lymphocytes from days 0, 39 8, 11 and 14. Figure 2 displays relative absorbance units at 405 nm from the ELISA assay for assays performed on lymphocytes from baboons A (1E6) and C (MOPC21) on days 0, 1-5, 8 and 11.

For baboon B, T cell dependent B cell Ig production decreased on the second day of 1E6 injections and remained at about 35% of the day zero value through day eleven (Figure 1).

For baboon A, Ig production was higher on days 1-11 as compared to the level before the injection. This is likely due to the lower 1E6 serum level achieved in baboon A versus baboon B. If Ig production levels observed on days one through four are taken as a base value, then a 40% inhibition of Ig secretion was observed on day five, and a inhibition on day eleven (Figure 2).

In baboon C, after injection with MOPC21, peripheral blood lymphocytes showed increased levels of Ig production between days two and eleven as compared 20 to the level on day zero.

2. T cell Proliferation Assay In a T cell proliferation assay, we measured the ability of activating anti-CD2 monoclonal antibodies or phytohemagglutinin to cause 25 proliferation of T cells isolated from baboons A, B and C on days 0, 1-5, 8, 11 and 14. 1 x 105 peripheral blood lymphocytes per well were incubated with anti-CD2 monoclonal antibodies Til1 and T11 3 at a 1:900 dilution of ascites fluid, in medium alone, or with PHA (Sigma Chemical Corporation, St. Louis, Missouri) (10 Ag/ml) for three days. After three days, cells were labelled with i gCi/well 3 HdT for 18 hours and then harvested. (Data not shown.) 40 Peripheral blood lymphocytes from baboon

B

showed no increase of 3 HdT incorporation in response to activating anti-CD2 monoclonal antibodies and very low proliferative activity in medium on days zero to fourteen.

Peripheral blood lymphocytes from baboon A responded to anti-CD2 monoclonal antibodies and PHA.

After day four, proliferation in response to those agents was inhibited about nine fold and remained low until at least day fourteen.

Peripheral blood lymphocytes from baboon C, the MOPC21 control, showed very low proliferative activity at all time points tested, under all conditions.

The significance of the data obtained is not clear because of irreproducibility of T cell proliferation in baboon C and day zero results for baboons A, B and C.

Example 3 20 Effect Of Administration Of LFA3TIP On Lymphocyte Function A. Administration And Sampling Protocols Two outbred, adult baboons (4.6 and 7.4 kg) (Paico anubis) were given bolus injections of 3 mg/kg 25 of purified LFA3TIP (obtained from Biogen, Inc., Cambridge, Massachusetts), by portacatheter once daily for five consecutive days. Blood was drawn from the baboons once before the first injection of antibody ~and then, daily for five days, 24 hours after each injection. Blood was also drawn on day 8, day 10, day 15, and day 22, where day 1 is the day of the first injection. This administration and sampling protocol was used for all of the assays described in this example, unless otherwise stated.

41 B. Toxicology Study With LFA3TIP The general toxicity of LFA3TIP and its potential effect on the physical condition, hematology and blood chemistry of baboons were evaluated. The general physical condition of the baboons remained unchanged throughout the study. No obvious or immediate side effects could be observed. Hematology and blood chemistries generally remained normal. In particular, Na+, C1-, creatine, blood urea nitrogen and liver enzymes AST and ALT levels all remained within normal limits. In addition, blood cell counts, including hematocrit, white blood cells, lymphocytes, monocytes, segmented neutrophils, and eosinophils, generally stayed within normal ranges. The ratio of CD4/CD8 expressing cells also stayed within normal ranges.

Plasma levels of LFA3TIP 10 days after the last injection were still about 32% of the LFA3TIP levels immediately following the last injection, which :20 indicates a much longer half-life than generally observed with murine monoclonal antibodies.

Fluorescent labeling of CD4 and CD8 expressing cells indicated that about 10% of CD4 cells and about 90% of CD8 cells were still coated with LFA3TIP 10 days after the last injection.

Example 4 Baboon Cardiac Alloqraft Model A. 1E6 Treatment An experimental primate cardiac allograft 30 model where baboon hearts were transplanted heterotopically in a nonfunctioning position into the necks of ABO-matched outbred baboons (Paio anubis) was used to assess the effect of anti-LFA-3 monoclonal 42 antibody 1E6 on allograft rejection. The protocol used was substantially as described in Michler et al., "Techniques For Primate Heterotopic Cardiac Xenotransplantation," J. Med. Primatol., 14, pp. 357-62 (1985), except that an allograft not a xenograft was performed.

Purified 1E6 prepared as described above was injected into one adult baboon (weight 32 kg) at a dose of 5 mg/kg, starting on day one, for 2 consecutive days before the transplant. On the third day, a cardiac heterotopic allograft transplant was performed with a heart from a young, 3 kg baboon. One dose of 5 mg/kg of 1E6 was injected on the day of the transplant and then once a day for ten consecutive days. Blood samples were collected two days before transplantation, prior to injection. Blood samples were also collected coincident with transplantation and on the fifth, tenth, sixteenth, nineteenth and twenty-first day after transplantation. An assay for total 1E6 serum levels 20 and the proportion of active 1E6 in the serum, i.e., the percentage of 1E6 capable of binding to LFA-3, was performed as described in Example 2C. No general immunosuppressive agents were administered to the baboon.

The graft was palpated on a daily basis and monitored by palpation and visual assessment of heart beat. Electrocardiograms were performed on a weekly basis. A percutaneous endomyocardial biopsy was performed on the sixteenth day after transplantation.

30 All blood chemistry and cell counts performed on the above described blood samples were within the normal limits.

Untreated control cardiac allografts in this model system were rejected a mean of 9±3 days after implantation in non-immunosuppressed baboons 43 (Rose et al., "Cardiac Xenotransplantation", Progress In Cardiovascular Diseases, 33, pp. 105-17 (1990)).

Rejection is defined, for the purposes of this model system, as swelling and hardening of the heart, and cessation of heart beat as measured by an electrocardiogram. In addition, progressive infiltration of lymphocytes in the myocardium, production of lymphocytotoxic antibodies and reaction to donor peripheral blood lymphocytes are monitored.

Survival of a graft in this system for longer than nine days, without immunosuppressive therapy, indicates an increased level of tolerance.

In the 1E6 treated baboon, the transplanted allogeneic heart was still beating twenty-three days after the transplant. Thus, 1E6 dramatically improved tolerance for a cardiac allograft.

B. LFA3TIP Treatment Using procedures substantially as described in Example 4A, the effect of LFA3TIP on cardiac i 20 allograft rejection is assessed. Purified LFA3TIP (described supra) is injected into one adult baboon at a dose of 3 mg/kg on day one for 2 consecutive days before the transplant. On the third day a cardiac heterotopic allograft transplant is performed with a heart from a young baboon. One dose of 3 mg/kg LFA3TIP is injected on the day of the transplant and then once a day for nine consecutive days.

The schedule of blood sample collection and analysis, and assessment of allograft rejection, is substantially as described in Example 4A.

Survival of the graft in the baboon that is treated with LFA3TIP is extended, compared to graft survival in untreated baboons, indicating increased graft tolerance due to LFA3TIP.

44 Deposits Murine hybridoma cells and antibodies useful in the present invention are exemplified by cultures deposited under the Budapest Treaty with American Type Culture Collection, Rockville, Maryland, on March 5, 1991, and identified as: Designation ATCC Accession No.

1E6 HB 10393

HC-

1B 11 HB 10694 7A6 HB 10695 8B8 HB 10696 E. coli JA221 transformed with plasmid pSAB152 (encoding LFA3TIP) was deposited under the Budapest Treaty with American Type Culture Collection on October 1, 1991 and identified as: Designation ATCC Accession No.

pSAB 1 5 2 68720 A bacteriophage carrying a plasmid encoding transmembrane LFA-3 was deposited under the Budapest 20 Treaty with In Vitro International, Inc., Linthicum, Maryland, on May 28, 1987. This deposit was transferred to American Type Culture Collection on June 20, 1991 and identified as: Designation ATCC Accession No.

25 AHT16[AgtlO/LFA-3] 75107 E. coli transformed with a plasmid encoding PI-linked LFA-3 was deposited under the Budapest Treaty with In Vitro International, Inc. on July 22, 1988.

This deposit was transferred to American Type Culture 30 Collection on June 20, 1991 and identified as: Designation ATCC Accession No.

p24 68788

C.

C C C C 45 SecNences set

SEQ

SEQ

SEQ

SEQ

SEQ

SEQ

SEQ

SEQ

The following is a summary of the sequences forth in the Sequence Listing: ID NO:1 DNA sequence of transmembrane LFA-3 ID NO:2 Amino acid sequence of transmembrane LFA-3 ID NO:3 DNA sequence of PI-linked LFA-3 ID NO:4 Amino acid sequence of PI-linked LFA-3 ID NO:5 DNA sequence of CD2 ID NO:6 Amino acid sequence of CD2 ID NO:7 DNA sequence of LFA3TIP ID NO:8 Amino acid sequence of LFA3TIP While we have hereinbefore described a number of embodiments of this invention, it is apparent that our basic embodiments can be altered to provide other embodiments that utilize the processes of this invention. Therefore, it will be appreciated that the scope of this invention includes all alternative embodiments and variations which are defined in the foregoing specification and by the claims appended 20 hereto; and the invention is not to be limited by the specific embodiments that have been presented herein by way of example.

-46- SEQUENCE LISTING GENERAL INFORMATION: APPLICANT: WALLNER, Barbara P.

BENJAMIN, Christopher D.

(ii) TITLE OF INVENTION: METHODS OF IMPROVING ALLOGRAFT OR XENOGRAFT TOLERANCE BY ADMINISTRATION OF LFA-3 OR CD2 BINDING PROTEINS (iii) NUMBER OF SEQUENCES: 8 (iv) CORRESPONDENCE

ADDRESS:

ADDRESSEE: c\o FISH NEAVZ- STREET: 875 Third Avenue CITY: New York STATE: New York COUNTRY: U.S.A.

ZIP: 10022 COMPUTER READABLE FORM: MEDIUM TYPE: Floppy disk COMPUTER: IBM PC compatible OPERATING SYSTEM: PC-DOS/MS-DOS SOFTWARE: PatentIn Release Version #1.25 (vi) CURRENT APPLICATION DATA: APPLICATION

NUMBER:

FILING DATE:

CLASSIFICATION:

(vii) PRIOR APPLICATION

DATA:

APPLICATION NUMBER: US 07/772,705 FILING DATE: 07-OCT-1991 (viii) ATTORNEY/AGENT INFORMATION: NAME: Haley Jr., James F.

REGISTRATION NUMBER: 27,794 REFERENCE/DOCKET NUMBER: B162CIP (ix) TELECOMMUNICATION

INFORMATION:

TELEPHONE: (212) 715-0600 INFORMATION FOR SEQ ID NO:l: SEQUENCE CHARACTERISTICS: LENGTH: 753 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear -47- (ix) FEATURE:. NAME/KEY: CDS LOCATION: 750 (ix) FEATURE:

NAME/KEY:

LOCATION:

(ix) FEATURE:

NAME/KEY:

LOCATION:

sigpeptide 1. .84 mat peptide 85. .750 (ix) FEATURE: NAME/KEY: misc feature LOCATION: 750 OTHER INFORMATION: /note- "Human transmembrane LFA-3" (ix) FEATURE: NAME/KEY: misc feature LOCATION: 646. .714 OTHER INFORMATION: /note- "Transmembrane domain" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l:

ATG

Met -28 GTT OCT GGG Val.Ala Gly -25 AGO GAC GOG GOC Ser Asp Ala Oly

CG

Arg -20 0CC CTG GOO GTC Ala Leu Gly Val OTO AGC GTG Leu Ser Val GTC TOO CTG Val Cys Leu CTG CAC TGO TTT GOT TTC Leu His Cys Phe Gly Phe -5 ATO AGO TOT TTT TOO CAA CAA Ile Ser Cys Phe Ser Gin Gin 1

ATA

Ile 5 TAT GOT OTT OTO Tyr Gly Val Val

TAT

Tyr 10 000 AAT OTA ACT TTO OAT OTA OCA AGO Gly Asn Val Thr Phe His Val Pro Ser

AAT

Asn a.

a a a. a.

a a a a. a GTO COT TTA AAA Val Pro Leu Lys OTO OTA TOG AAA Val Leu Trp Lys

AAA

Lys 30 CAA AAO OAT AAA Gin Lys Asp Lys OTT OCA Val Ala MAT A-CC Asn Arg 144 192 240 288 GAA OTG CAA Glu Leu Glu OTT TAT TTA Val Tyr Lau

A-AT

A-sn TOT GMA 'TO AGA Ser Glu Phe Arg

GOT

Ala 45 'ITO TOA TCT TTT Phe 5cr Ser Phe

A

Lys GAO ACT GTG TCA Asp Thr Val Ser AGO OTO ACT ATO Ser Leu Thr Ile

TAO

Tyr AAC TTA A-CA Asn Lau Thr TOA TOA 5cr Ser GAT GMA OAT GAG Asp Glu Asp Clu

TAT

Tyr 75 CMA ATO GMA TOG OCA MAT ATT ACT OAT Glu Met Olu Ser Pro A-sn Ile Thr Asp ACC ATG MAG 'TOC 'TT OTT Thr Met Lys Phe Phe Leu 85 90 TAT OTO OTrT GAG Tyr Val Leu Glu OTT OCA TOT CCC Leu Pro Ser Pro

A-CA

Thr 100 -48- CTA ACT TGT GCA Leu Thr Cys Ala TLGJ ACT AAT GGA Leu Thr Asn Gly 105 AAC AGC CAT CGA Asn Ser His Arg AGC ATT GMA GTC CMA TCC ATG ATA Ser fle Giu Val Gin Cys Met Ile CCA GAG CAT Pro Giu His TGT CCT ATG Cys Pro Met 135

TAC

Tyr 120 GGA CTT ATA ATO TAC Gly Leu Ile Met Tyr 125

TCA

Se r TOG GAT Trp Asp GAG CAA TOT AMA Oiu Gin Cys Lys

CGT

Arg 140 MAC TCA ACC ACT Asn Ser Thr Ser

ATA

Ile TAT TTT MAG Tyr Phe Lys ATG GMA Met Giu 150 MAT CAT GTT CCA Asn Asp Leu Pro

CMA

Gin 155 AAA ATA GAG TOT LYS Ile Gin Cys

ACT

Thr CTT AGC MAT CCA Leu Ser Asn Pro 432 480 528 5 76 624 672 720 753

TTA

Leu 165 TTT MAT ACA ACA Phe Asn Thr Thr

TGA

Ser 170 TCA ATG ATT TTG Ser Ile Ile Leu

ACA

Thr ACC TGT ATO CCA Thr Cys Ile Pro

AGC

Ser AGC GGT CAT TCA Ser Oly His Ser

AGA

Arg 185 GAC AGA TAT OCA His Arg Tyr Ala

CT'

Leu ATA CCC ATA CCA Ile Pro Ile Pro TTA GCA Leu Ala GTA ATT ACA Val Ile Thr

ACA

Thr 200 TOT ATT GTG CTG Cys Ile Val Leu

TAT

Tyr ATO MAT GGT ATT Met Asn Oly Ile CTO MAA TGT Leu Lys Cys 210O GAG AGA AAA CCA GAG AGA ACC Asp Arg Lys Pro Asp Arg Thr 215 MGC TG MAT TGA Asn Ser Asn 220 t C, INFORMATION FOR SEQ ID NO:2: SEQUENCE

GHARACTERISTICS:

LENGTH: 250 amino acids TYPE: amino acid TOPOLOGY: linear (ii) MOLECUJLE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: Met Val Ala Gly Ser A-sp Ala Gly Arg Ala Leu Oly -28 -25 -20 Val Gys Leu Leu His Gys Phe Cly Phe Ile Ser Gys -10 -5 Ile Tyr Oly Val Val Tyr Oly Asn Val Thr Phe His 10 15 Val Pro Leu Lys Glii Val Leu Trp Lys Lys Gin Lys 30 '9 @9 9 Val Leu Ser Val Phe Ser Cmn Gin Val Pro Ser Asn 0 S ASP Lys Val Ala -49- Glu Leu Val Tyr Glu Asn Ser Glu Leu Asp Thr Val Phe Arg Ser Cay 60 Ala Phe 45 Ser Leu Ser Ile Lys Asn Arg Asn Leu Thr Se Thl Let Pro Gys Met Leu 165 Ser Val Asp r Ser Met Thr Glu Pro Glu 150 Phe j Gly I Asp Ciu Asp Clu Lys Cys His Met 135 Asn ksn is Phe Ala Tyr 120 Clu Asp Thr Ser Phe Leu 105 Asn Gin Leu Thr Arg 185 Leu Thr Ser Gys Pro Ser 170 His Tyr 75 Tyr Asn His Lys Cln 155 Ser Arg Clu Met Ciu Ser Pro Val Cly Arg Arg 140 Lys Ile Tyr Leu Ser Gly 125 Asn Ile Ile Ala Glu Ile 110 Leu Ser Gin Leu Leu Ser 95 Clu Ile Thr Cys Thr 175 Ile Leu Val Met Ser Thr 160 Thr Pro Asn Pro Cin Tyr Ile 145 Leu Cys Ile Ile Ser Cys Ser 130 Tyr Ser Ile Pro Thr Pro Met 115 Trp Phe Asn Pro Leu Asp Thr 100 Ile Asp Lys Pro Ser 180 Ala 190 195 Thr Lys 215 Thr 200 Pro Cys Asp Ile Arg Val Thr Leu Asn 220 Tyr 205 Ser Met Asn Asn Cly Ile Leu Lys Cys 210 e

S

S.

*5 0

S.

SS

*5 000S INFORMATION FOR SEQ ID NO:3: SEQUENCE CHARACTERISTICS: LENGTH: 723 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (ix) FEATURE: NAME/KEY:

CDS

LOCATION: 1..720 (ix) FEATURE: NAME/KEY: sigpeptide LOCATION: 1..84 (ix) FEATURE:

NAME/KEY:

LOCATION:

mat peptide 85. .720 (ix) FEATURE: NAME/KEY: misc feature LOCATION: 1..720 OTHER INFORMATION: /note- "Human Fl-linked LFA-3" (ix) FEATURE: NAME/KEY: misc feature LOCATION: 568..720 OTHER INFORMATION: /note- "Signal Fl-linkage" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: sequence for ATG OTT OCT 000 Met Val Ala Gly -28 -25 GTC TOO CTG CTG Val Gys Leu Leu AGC CAC GC Ser Asp Ala GOO COO CCC OTO COO Oly Arg Ala Leu Oly 010 010 AGO OTO Val Leu Ser Val CAC TOO TTT COT TTC ATO AOC TOT TTT TOC CAA CAA His Gys Phe Oly Phe Ile Ser Cys Phe Ser Gin Gln

ATA

Ile TAT OCT OTT 010 Tyr Oly Val Val

TAT

Tyr 10 000 MAT OTA ACT TTC CAT CIA OCA AGO Gly Asn Val Thr Phe His Val Pro Ser

MAT

Asn 48 96 144 192 240 288 OTO OCT TIA AMA Val Pro Leu Lys

GAG

O lu 25 OTO CTA TOG AMA Val Leu Trp Lys AMA CMA AO GAT AMA Lys Cmn Lys Asp Lys 30 GT-r OCA Val Ala GAA OTO GMA Olu Leu Olu OTT TAT TIA Val Tyr Leu TOT GAA TO AGA Ser Olu Phe Arg

GOT

Ala 45 TIC TbA TOT TT Phe Ser Ser Phe AA MT AGO Lys Asn Arg MOC TTA ACA Asn Leu Thr GAO ACT GTC TOA Asp Thr Val Ser

OCT

Oly 60 AGO OTO ACT ATO Ser Leu Thr Ile

TAO

Tyr TOA TCA Ser Ser 70 GAT GMA OAT GAG Asp Glu Asp Glu GMA ATO GMA TOO Clu Met Glu Ser

OCA

Pro MAT ATI ACT OAT Asn Ile Thr Asp

ACC

Thr ATO MCG TTC TT Met Lys Phe Phe

OTT

Leu 90 TAT 010 CIT GAG TCT OTT OCA TOT COO Tyr Val Leu Clu Ser Leu Pro Ser Pro

ACA

Thr CIA ACT TOT OCA Leu Thr Cys Ala OCA GAG CAT TAO Pro 0Th His Tyr 120

TTO

Le u 105 ACT MAT OGA AGO Thr Asn Oly Ser AlT I le 110 GMA 010 CMA TGO ATG ATA Glu Val Gin Cys Met Ile 384 432 480 MOC AGO OAT CA Asn Ser His Arg OCA OTT ATA ATO TAO Oly Leu Ile Met Tyr 125

TCA

Ser 130 TGG CAT Tr-p Asp -51- TGT CCT ATG GAG Cys Pro Met Giu 135 CAA TGT AAA CGT MAC TCA ACC AGT ATA TAT TTT -AAG Gin Cys Lys Arg Asn Ser Thr Ser Ile Tyr Phe Lys ATG GAA MAT Met Glu Asn 150 GAT CTT CCA Asp Leu Pro

CAA

Gin 155 AAA ATA CAG TGT Lys Ile Gin Cys

ACT

Thr 160 CTT AGC MAT CCA Leu Ser Asn Pro

TTA

Leu 165 TTT MAT ACA ACA Phe Asn Thr Thr

TCA

Ser 170 TCA ATC ATT TTG Ser Ile Ile Leu

ACA

Thr 175 ACC TGT ATC CCA Thr Cys Ile Pro

AGC

Ser 180 624 672 AGC GGT CAT TCA Ser Gly His Ser AGA CAC AGA TAT GCA CTT Arg His Arg Tyr Ala Leu 185 ,190 ATA CCC ATA CCA Ile Pro Ile Pro TTA GCA Leu Ala GTA ATT ACA Val Ile Thr

ACA

Thr 200 TOT ATT OTO CTG Cys Ile Val Leu

TAT

Tyr 205 ATO MAT OCT ATG Met Asn Gly Met TAT OCT TTrr Tyr Ala Phe 210

TMA

INFORMATION FOR SEQ ID NO:4: SEQUENCE CHARACTERISTICS: LENGTH: 240 amino acids TYPE: amino acid TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: a a.

a. Met Val Ala Oly Ser Asp -28 -25 Ala Gly Arg -20 Ala Leu Gly Val Le u Ser Val Ser Gin Gin Val Cys Leu Leu His Cys Phe Oly -5 Phe Ile Ser Cys Phe 1 Tyr Gly Val Val Tyr 10 Oly Asn Val Thr His Vai Pro Ser Asn *a.

a.

a Val Pro Leu Lys Giu 25 Val Leu Trp Lys Gin Lys Asp Lys Val Ala Olu Leu Oiu Asn Ser Giu Phe Arg Ala 45 Phe Ser Ser Phe Lys A-sn Arg Asn Leti Thr Val Tyr Leu Asp Thr Val Ser Gly Ser Leu Thr Ile Tyr Ser Ser Asp Oiu Asp Oiu Tyr Giu Met Oiu Ser Pro Asn Ile Thr Asp 7r -52- Thr Met Lys Phe Phe Leu Tyr Val Leu Glu Ser Leu Pro Ser Pro Thr 90 95 100 Leu Thr Cys Ala Leu Thr Asn Gly Ser lie Glu Val Gin Cys Met lie 105 110 115 Pro Glu His Tyr Asn Ser His Arg Gly Leu lie Met Tyr Ser Trp Asp 120 125 130 Cys Pro Met Glu Gin Cys Lys Arg Asn Ser Thr Ser Ile Tyr Phe Lys 135 140 145 Met Glu Asn Asp Leu Pro Gin Lys lie Gin Cys Thr Leu Ser Asn Pro 150 155 160 Leu Phe Asn Thr Thr Ser Ser lie lie Leu Thr Thr Cys Ile Pro Ser 165 170 175 180 Ser Gly His Ser Arg His Arg Tyr Ala Leu Ile Pro Ile Pro Leu Ala 185 190 195 Val Ile Thr Thr Cys Ile Val Leu Tyr Met Asn Gly Met Tyr Ala Phe 200 205 210 INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: S: LENGTH: 1056 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (ix) FEATURE: NAME/KEY: CDS LOCATION: 1..1053 (ix) FEATURE: NAME/KEY: sig_peptide LOCATION: 1..72 (ix) FEATURE: NAME/KEY: mat_peptide LOCATION: 73..1053 (ix) FEATURE: NAME/KEY: misc feature LOCATION: 1..1053 OTHER INFORMATION: /note- "Human CD2" (ix) FEATURE: NAME/KEY: misc feature LOCATION: 628..702 OTHER INFORMATION: /note- "Transmembrane domain" -53- (xi) SEQUENCE DESCRIPTION: SEQ ID ATG AGC Met Ser -24 TrT CCA TCT AAA TTT GTA Ph. Pro Cys Lys Phe Val -20 CCC ACC TTC CTT Ala Ser Phe Leu -15 GTT TCT TCC Val Ser Ser AAA GGT GCA GTC TCC AAA GAG ATT ACG Lys Gly Ala Val Ser Lys Glu Ile Thr 1 CTG ATT TTC AAT Leu Ile Phe As AAT GCC TTG GAA Asn Ala Leu Glu ATT CCT ACT TTT Ile Pro Ser Phe ACC TGG Thr Trp GGT GCC TTG GGT Gly Ala Leu Gly

CAG

Gln is GAC ATC AAC TTG Asp Ile Asn Leu

GAC

Asp 48 96 '144 192 240

CAA

Gln ATG ACT CAT CAT Met Ser Asp Asp

ATT

Ile 30 GAC CAT ATA AAA Asp Asp Ile Lys

TOG

Trp 35 CAA AAA ACT TCA Glu Lys Thr Ser

GAG

Asp AAC AAA AAG ATT Lys Lys Lys Ile

OCA

Ala CAA TTC AGA AAA Gin Phe Arg Lys

GAG

Glu 50 AAA GAG ACT TTC Lys Clu Thr Phe AAG CAA Lys Glu AAA CAT ACA Lys Asp Thr CTC AAG ACC Leu Lys Thr

TAT

Tyr AAG CTA TTT AAA Lys Leu Phe Lys

AAT

Asn 65 CGA ACT CTG AAA Gly Thr Leu Lys ATT AAG CAT Ile Lys His TAT CAT ACA Tyr Asp Thr CAT GAT GAG CAT Asp Asp Gin Asp

ATC

Ile 80 TAG AAC GTA TCA Tyr Lys Vai Ser AAA OGA Lys Gly 90 AAA MT GTC TTG Lys Asn Val Leu AAA ATA TTT CAT Lys Ile Phe Asp

TTO

Leu 100 AAC ATT CAA GAG Lys Ile Gin Glu 288 336 384 432 480

AGG

Arg 105 GTC TCA AAA CCA Val Ser Lys Pro

AAG

Lys 110 ATC TCC TGG ACT Ile Ser Trp Thr

TOT

Cys 115 ATC AAC ACA ACC Ile Asn Thr Thr

CTC

Leu 120 ACC TGT GAG GTA Thr Cys Giu Val AAT GGA ACT GAC Asn Gly Thr Asp

CCC

Pro 130 GAA TTA AAC CTC Giu Leu Asn Leu TAT CAA Tyr Gin 135 CAT GGG AAA CAT CTA AAA OTT TCT Asp Gly Lys His Leu Lys Leu Ser 140

CAG

Cln 145 AGC CTC ATC ACA Arg Val Ile Thr CAC AAC TGG His Lys Trp 150 AAC AAA CTC Asn Lys Vai ACC ACC AGO Thr Thr Ser 155 CTO AGT GGA AAA Leu Ser Ala Lys AAG TG ACA GCA Lys Cys Thr Ala 576 AGC AAG Ser Lys 170 GAA TCC ACT CTC Ciu Ser Ser Val GAG CCT CTC AOC TOT Ciu Pro Val Ser Cys 175

CCA

Pro 180 GAG AAA GOT CTC Glu Lys Gly Leu -54- GAC ATC TAT CTC Asp Ile Tyr Leu 185 GTC TTT GTG GCA Val Phe Val Ala ATC ATT GGC ATA TGT GGA Ile Ile Gly Ile Cys Gly GGA GGC AGC Gly Gly Ser 195 ACC MAA AGG Thr Lys Arg

CTG

Leu 205 CTC cr1' rrc TAT Leu Val Phe Tyr

ATC

Ile 210 CTC7TTG ATG Leu Leu Met 200 MAA AAA GAG LYS Lys Gin 215 CAC AGA GTA His Arg Val 230 GCT TCA ACC Ala Ser Thr 672 720 768 816 AGO AGT CGG Arg Ser Arg GCT ACT GMA Ala Thr Giu 235

AGA

Arg 220 MAT OAT GAG GAG Asn Asp Giu Giu

CTO

Leu 225 GAG ACA AGA GCC Glu Thr Arg Ala GMA AGO GOC CG Giu Arg Oly Arg

MAG

Lys 240 CCC CAC CMA Afl Pro His Gin Ile

CCA

Pro CCT GAG Pro Gin 250 MAT CCA OCA ACT Asn Pro Ala Thr

TCC

Ser 255 CMA CAT CCT CCT Gin His Pro Pro

CCA

Pro 260 CCA OCT GOT CAT Pro Pro Gly His

CGT

Arg 265 TCC CG GA CCT Ser Gin Ala- Pro CAT COT CCC CCG His Arg Pro Pro CCT OGA CAC COT Pro Gly His Arg orr Val GAG GAG GAG CGT Gin His Gin Pro

GAG

Gin 285 MAG AGO GGT CGT LYS Arg Pro Pro

OCT

Ala 290 CCG TCG 0CC ACA Pro Ser Gly Thr Gin Val 295 CCA A Pro Lys 864 912 960 1008 1053 GAG CG GAG His Gin Gin

A

Lys 300 0CC CCG CCC CTC Gly Pro Pro Leu 9 9* 9

CCC

Pro 305 AGA CCT OGA Cr1' Arg Pro Arg Val

CAG

Gin GCT CCC CAT CCC GCA OCA GAA MGC TCA TTG Pro.Pro His Gly Ala Ala Ciu Asn Ser Leu 315 320 TGC GGT TCC TCT MAT Ser Pro Ser Ser Asn 325

TAA

1056 INFORM{ATION FOR SEQ ID NO:6: SEQUENCE

CHARACTERISTICS:

LENGTH: 351 amino acids TYPE: amino acid TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: Met Ser Phe Pro Gys Lys Phe Val Ala Ser Phe Leu Leu Ile Phe Asn -24 -20 -15 Val Ser Ser Lys Gly Ala Vai Ser Lys iu Ile Thr Asn Ala Leu Glu 1

C

Thr Gin Lys Lys Len Lys G Arg V 105 Thr C' Asp G~ Tr He

LY~

sp ly al Ly p Gi 0 t Se 3Ly )Th2 Thi Lys Ser C iu Lys .y Al r As; S Ile r Tyr 60 Asp Asn Lys Val His 140 a Leu Gly Gin Asp 15 SAsp Ile Asp Asp 30 Ala Gin Phe Arg Lys Leu Phe Lys Asp Gin Asp Ile Val Leu Giu Lys 95 Pro Lys Ile Ser T 110 Met Asn Gly Thr A 125 Len Lys Len Ser G 1 Ile As Ile Ly Lys Gli Asn G1 65 ryr Lys Ele Phe ~rp Thr .sp Pro 130 in Arg 45 n Len Asp Ile s Trp Giu Lys 35 u Lys Giu Thr 0 SThr Len Lys Vai Ser Ile Asp Leu Lys i00 Cys Ile Asn 115 .Giu Leu Asn Val Ile Thr H Pr Th Ile Tyr Ile rhr .eu [is Ser Ser Lys Lys Asp Gin Thr Tyr C 135 Lys TI Phe Asp Giu His Thr Glu Zen ;In rp 1 Thr Thr Ser Len Ser Ala Lys Phe Lys Cys Thr Al~ Ser Asp 185 Val Arg Ala Pro4 Arg 265 Lys 170 Ile Phe Ser Thr Gln 250 Ser 155 Gin Tyr Val1 Arg Glu 235 Asn GIn Ser Len Ala Arg 220 Gin Pro kla Ile Len 205 Asn Arg Ala Pro Val Ile 190 Len Asp G ly Thr Ser 270 Glu 175 G ly Val Gin Arg Ser 255 His 160 Pro Ile Phe C iu Lys 240 Gin Arg Val Cys Tyr Le u 225 Pro His Pro Ser Gly Ile 210 Gin His Pro Pro Gys Gly 195 Thr Thr Gin Pro Pro Pro 180 Gly Lys Arg Ile Pro 260 Pro Gly 165 Gin Ser Arg Ala Pro 245 Pro Gly Lys Leu Lys His 230 Ala Pro His Gly Len Lys 215 Arg Ser G ly Arg Len Met 200 Gin Val Thr His Val Asn Lys Val Gin His Gin Pro Gln 285 Lys Arg Pro Pro Ala 290 Pro Ser Giy Thr Gin Val 295 -56- His~ Gin Gin Lys Gly Pro Pro Leu Pro Arg Pro 300 305 Pro Pro His Gly Ala Ala Glu Asn Ser Leu Ser 315 320 INFORMATION FOR SEQ ID NO:7: SEQUENCE CHARACTERISTICS: LENGTH: 1050 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (iii) HYPOTHETICAL:

NO

(iv) ANTI-SENSE:

NO

(ix) FEATURE: NAME/KEY:

CDS

LOCATION: l. .1041 Arg Val Gln Pro Lys 310 Pro Ser Ser Asn 325 (ix) FEATURE:

NAME/KEY:

LOCATION:

(ix) FEATURE:

NAME/KEY:

LOCATION:

sigpeptide 1. .84 mat peptide 85. .1041 0 a a.

*t.

a (ix) FEATURE: NAME/KEY: misc feature LOCATION: 85. .1041 OTHER INFORMATION: /note- (ix) FEATURE: NAME/KEY: misc feature LOCATION: 360. .361 OTHER INFORMATION: /note- "LFA3TIP" ".FA-3/IgG fusion point' (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

S

ATO GTT GCT GGG AGC GAC GCG GCC Met Val Ala Gly Ser Asp Ala Cly -28 -25 CTC TGC CTG CTG CAC TCC TTT CCT Val Cys Leu Leu His Cys Phe Cly 10 -5 CCC CCC CTC CCC GTC CTC AGC GTG Arg Ala L.eIu Cly Val Leu 5cr Val -20 TTC ATC ACC TGT TTT TCC CAA cAA Phe Ile Ser Cys Phe Ser Gln Gln 1 48 96 14-

ATA

I le TAT GGT Gt-r GTG Tyr Gly Val Val

TAT

Tyr 10 CCC AAT CTA ACT TI'C CAT CTA CCA Gly Asn Val Thr Phe His Val Pro 15 ACC AAT Ser Asn -57- GTG CCT TTA Val Pro Lau AAA GAG GTC Lys Git' Val CTA TGG AAA AAA CAA MG GAT AAA Let' Trp, Lys Lys Gin Lys Asp Lys 30 GTT GCA Val Ala GMA CTG GMA Glu Leu Glu GTT TAT TTA Val Tyr Let' AAT TCT Asn Ser GMA TTC AGA Git' Phe Arg TTC TCA TCT TTT Phe Ser Ser Phe AA MT AGO Lys Asn Arg MAC TTA ACA Asn Leu Thr GAC ACT GTG TGA Asp Thr Val Ser

OCT

Gly 60 AGC CTC ACT ATC Ser Leu Thr Ile 240 288 336 TCA TCA Ser Ser GAT GMA GAT GAG Asp Git' Asp Git' GMA ATG GMA TCG Git' Met Git' Ser

CCA

Pro MAT ATT ACT GAT Asn Ile Thr Asp

ACC

Thr ATG MAG TTC TTT Met Lys Phe Phe

CTT

Leu 90 TAT GTC GAC AAA ACT CAC ACA TGC CCA Tyr Val Asp Lys Thr His Thr Cys Pro 95

CCC

Pro TGC CCA GCA GGT Cys Pro Ala Pro

GMA

C lu 105 CTC CTC CCC GGA Leu Let' Cly Cly

CCC

Pro 110 TCA GTC TTC CTC Ser Val Phe Leu TTC CCC Phe Pro 432 CCA AAA CCC Pro Lys-Pro TGC GTG GTC Gys Val Val 135

MAG

Lys 120 GAC ACC CTC ATO Asp Thr Leu Met TCG CCC ACC CCT Ser Arg Thr Pro GAG CTC ACA Git' Vai Thr 130 MOG TTC MAC Lys Phe Asn 480 CTG CAC GTG AC GAG GAA GAC CCT GAG Val Asp Val Ser His Git' Asp Pro Giu 140 a.

S.

a a. a a.

a.

a a.

TOG TAG Trp, Tyr 150 CTG CAC CCC CTC Val Asp Cly Val

GAG

Glu 155 CTC CAT MAT CC Val His Asn Ala ACA MAG CCG CCC Thr Lys Pro Arg 528 576 624 672

GAG

165 GAG GAG TAG MAC Giu Gin Tyr Asn ACC TAC CCC CTG Thr Tyr Arg Val

CTC

Val 175 ACC CTC CTC ACC Ser Val Let' Thr GTG GAG GAG GAG Let' His Gin Asp

TCC

Trp 185 CTG MAT CCC AAC Leu Asn Gly Lys

GAG

C iu 190 TAG MCG TCC MAG Tyr Lys Cys Lys GTC TCG Val Ser 195 CCC AMA Ala Lys MAC AAA GCC Asn Lys Ala CCC GAG CCC Cly Gin Pro 215

CTC

Let' 200 GCA CCC CCC ATC Pro Ala Prc, Ile

GAG

Clu 205 AAA ACC ATC 7CC Lys Thr Ile Ser

AMA

Lys 210 720 768 a a a CGA CMA CGA GAG Arg Git' Pro Gin

CTC

Val1 220 TAG ACC CTG CCC Tyr Thr Leu Pro

CCA

Pro 225 TCC CGC CAT Ser Arg Asp GAG CTG AGC MAG MGC GAG Git' Let' Thr Lys Asn Gin 230 CTC AC CTG ACC 7CC CTG Val Ser Leu Thr Cys Let' 235 240 GTC MAA GC TTC Val Lys Oly Phe 816 -58- TAT CCC AGC GAC ATC GCC GTG GAG Tyr Pro Sor Asp Ile Ala Val Glu 245 250 AAC AAC TAC AAG ACC ACG CCT CCC Asn Asn Tyr Lys Thr Thr Pro Pro 265 TTC CIC TAC AGC AAG CTC ACC GTG I Phe Leu Tyr Ser Lys Leu Thr Val 280 AAC GTC TIC TCA TGC TCC GTG ATG Asn Val Phe Ser Cys Ser Val Met 1 295 300 ACG CAG AAG AGC CTC TCC CTG TCT C Thr Gin Lys Ser Leu Ser Leu Ser P 310 315 TGG GAG AGC Trp Giu Ser 255 GTG CTG GAC Val Leu Asp 270 GAC AAG AGC Asp Lys Ser 285 -AT GAG CCI is Glu Ala CG GGT AAA ro Gly Lys AAT GGG GAG CCG GAG Asn Gly Gin Pro Glu 260 TCC GAC GGC TCC TTC Ser Asp Gly Ser Phe 275 AGG TGG GAG GAG GGG Arg Trp Gin Gin Gly 290 CTG CAC AAC CAC TAC Leu His Asn His Tyr 305

TGAGTGCGG

864 912 960 1008 1050 S 555

S

S

S

INFORMATION FOR SEQ ID NO:8: SEQUENCE

CHARACTERISTICS:

LENGTH: 347 amino acids TYPE: amino acid TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID t' Met Val Ala Gly Ser Asp Ala Gly Arg Ala L -28 -25 -20 Val Cys Leu Leu His Gys Phe Cly Phe Ile S -5 Ile Tyr Cly Val Vai Tyr Gly Asn Val Thr P 5 10 Val Pro Lau Lys Glu Val Leu Trp Lys Lys G 25 30 Giu Leu Giu Asn Ser Giu Phe Arg Ala Phe Si 40 45 Val Tyr Leu Asp Thr Val Ser Gly Ser Leu T1 60 Ser Ser Asp Giu Asp Glu Tyr Glu Met Glu Se 75 Thr Met Lys Phe Phe Leu Tyr Val Asp Lys Th 90 9 0:8: .eu Cly er Gys he His 15 In Lys er Ser ir Ile r Pro A 80 .r His J 5 Va1 Phe 1 Val Asp Phe Tyr ksn .hr Leu Ser Pro Lys Lys Asn lie Gys I Ser Gln Ser Va1 Asn Leu rhr ?ro Val Gin Asn Ala Arg Thr Asp Pro 100 -59- Cys Pro Ala P Pro Lys Pro L, Cys Val Val Vz 135 Trp Tyr Val As 150 Giu Giu Gin Ty 165 Leu His Gin As] Asn Lys Ala Let 200 Gly Gin Pro Arg 215 Glu Leu Thr Lys 230 Tyr Pro Ser Asp 245 Asn Asn Tyr Lys Phe Leu Tyr Ser 280 Asn Val Phe Ser 295 Thr Gin Lys Ser 310 ro Giu Leu Lou Gly Gly Pro Ser Val Phe 105 110 rs Asp Thr Lou Met Ile Ser Arg Thr Pro ?0 125 1i Asp Val Ser His Giu Asp Pro Giu Val 140 145 p Gly Val Glu Val His Asn Ala Lys Thr 155 160 r Asn Ser Thr Tyr Arg Val Val Ser Val 170 175 P Trp, Leu Asn Gly Lys Glu Tyr Lys Cys 185 190 1Pro Ala Pro Ile Glu Lys Thr Ile Scr 205 Glu Pro Gin Val Tyr Thr Leu Pro Pro S 220 225 Asn Gin Val Ser Leu Thr Cys Lou ValL 235 240 Ile Ala Val Giu Trp Glu Scr Asn Gly G 250 255 Thr Thr Pro Pro Val Leu Asp Ser Asp G 265 270 Lys Lou Thr Val Asp Lys 5cr Arg Trp G: 2852 Cys Ser Val Met His Giu Ala Lou His A.

300 305 Lou Ser Leu Ser Pro Gly Lys 315 Cl 13 Ly Ly, Le~ Lys -ys er ,ys in ly Ln ~u P1~ 11 ,u Va 0 Ph Pr Th *Val 195 Ala Arg G ly Pro 5cr 275 Gin His ec Pro .1 Thr e Asn 0 Arg Val 180 *Ser Lys Asp Phe Giu 260 Phe Gly Tyr Se.

S

S

CS

S

CC

Claims (47)

1. A method for improving tolerance of transplanted allograft tissue or xenograft tissue comprising the steps of administering to a human, the graft tissue and a monoclonal anti-LFA-3 antibody.

2. A monoclonal anti-LFA-3 antibody when administered with graft tissue for improving tolerance of transplanted allograft tissue or xenograft tissue in a human.

3. The use of a monoclonal anti-LFA-3 antibody for the preparation of a medicament to be administered with graft tissue for improving tolerance of transplanted allograft tissue or xenograft tissue in a human.

4. The method, antibody or use according to any one of claims 1 to 3, wherein the monoclonal anti-LFA-3 antibody inhibits T cell activation.

The method, antibody or use according to any one of claims 1 to 3, wherein the monoclonal anti-LFA-3 antibody is produced by a hybridoma selected from hybridomas having accession numbers ATCC HB 10693 (1E6), ATCC HB 10694 (HC-1Bll), ATCC HB 10695 (7A6), ATCC HIB 10696 (8B8) or is the monoclonal antibody TS2/9.

6. The method, antibody or use according to claim 5, wherein the monoclonal anti- LFA-3 antibody is produced by the hybridoma having accession number ATCC HB 10693 (1E6). 20

7. A method for improving tolerance of transplanted allograft tissue or xenograft tissue comprising the steps of administering to a human, the graft tissue and a soluble LFA- 3 polypeptide linked to a human immunoglobulin heavy chain hinge region and constant region, or portions thereof.

8. A soluble LFA-3 polypeptide linked to a human immunoglobulin heavy chain 25 hinge region and constant region, or portions thereof, when administered with graft tissue, for improving tolerance of transplanted allograft tissue or xenograft tissue in a human.

9. The use of a soluble LFA-3 polypeptide linked to a human immunoglobin heavy chain hinge region and constant region or portions thereof, for the preparation of a medicament to be administered with graft tissue, for the preparation of a medicament for improving tolerance of transplanted allograft tissue or xenograft tissue in a human.

10. The method, polypeptide or use according to any one of claims 7 to 9, wherein the soluble LFA-3 polypeptide linked to a human immunoglobulin heavy chain hinge region and constant region, or portions thereof is AAi-AA 92 of SEQ. ID NO. 2. S S. S S 55 S S. [I:\DayLib\LIBH]08724.doc:MCC 61

11. The method, polypeptide or use according to any one of claims 7 to 9, wherein the soluble LFA-3 polypeptide linked to a human immunoglobulin heavy chain hinge region and constant region, or portions thereof is AAi-AA 319 of SEQ. ID NO. 8.

12. The method, polypeptide or use according to any one of claims 7 to 9, wherein s the soluble LFA-3 polypeptide linked to a human immunoglobulin heavy chain hinge region and constant region, or portions thereof is LFA-3TIP.

13. The method, antibody, polypeptide or use according to any one of claims 1 to 3 or 7 to 9, wherein the graft tissue is a xenograft.

14. The method, antibody, polypeptide or use according to claim 13, wherein the graft tissue is a cardiac or renal xenograft.

The method, antibody, polypeptide or use according to any one of claims 1 to 3 or 7 to 9, wherein the graft tissue is an allograft.

16. The method, antibody, polypeptide or use according to claim 15, wherein the graft tissue is a cardiac or renal allograft.

17. The method, antibody or use according to any one of claims 1 to 3, wherein the graft tissue is perfused with an effective amount of the monoclonal anti-LFA-3 antibody before implantation into the mammal.

18. The method, antibody or use according to any one of claims 1 to 3, wherein the monoclonal anti-LFA-3 antibody is administered at a dose between about 0.01 and about 20 mg antibody/kg body weight.

19. The method, antibody or use according to claim 18, wherein the monoclonal anti-LFA-3 antibody is administered at a dose between about 0.1 and about 5 mg antibody/kg body weight.

20. The method, antibody or use according to claim 19, wherein monoclonal anti- LFA-3 antibody is administered at a dose between about 0. 1 and about 2 mg antibody/kg body weight.

21. The method, polypeptide or use according to any one of claims 7 to 9, wherein the soluble LFA-3 polypeptide is administered at a dose between about 0.01 and about 2 mg protein/kg body weight. 30

22. The method, polypeptide or use according to claim 21, wherein the soluble LFA-3 polypeptide is administered at a dose between about 0.01 and about 1 mg protein/kg body weight. [I:\DayLib\LIBH08724.doc:MCC

23. The method, antibody, polypeptide or use according to claim 15, wherein the antibody or the polypeptide is administered once per day for two consecutive days before the transplant and once per day for one to ten consecutive days after the transplant.

24. The method, antibody, polypeptide or use according to claim 23, wherein the antibody or the polypeptide is administered once per day for two consecutive days before the transplant and once per day for two consecutive days after the transplant.

The method, antibody, polypeptide or use according to claim 13, wherein before the transplant the antibody or the polypeptide is administered contemporaneously with tissue from the xenograft source.

26. The method, antibody, polypeptide or use according to claim 25, wherein the contemporaneous administration is followed by administration before the transplant of the antibody or the polypeptide.

27. The method, antibody, polypeptide or use according to claim 13, wherein the Santibody or the polypeptide is administered before the transplant once per day for two consecutive days, then contemporaneously with tissue from the xenograft source once per day for one day and then once per day for one to ten consecutive days.

28. The method, antibody, polypeptide or use according to claim 27, wherein the antibody or the polypeptide is administered before the transplant once per day for two consecutive days, then contemporaneously with tissue from the xenograft source once per 20 day for one day and then once per day for five to ten consecutive days.

29. The method, antibody, polypeptide or use according to claim 26, wherein the contemporaneous administration of the antibody or the polypeptide and the tissue from the xenograft source is simultaneous.

The method, antibody, polypeptide or use according to claim 25 or claim 27, wherein the tissue from the xenograft source is blood.

31. The method, antibody, polypeptide or use according to any one of claims 1 to *Oa 3 or 7 to 9, wherein the antibody or the polypeptide is administered intravenously, intramuscularly, subcutaneously, intra-articularly, intrathecally, periostally, orally, topically or by inhalation.

32. The method, antibody, polypeptide or use according to claim 31, wherein the antibody or the polypeptide is administered intravenously or intramuscularly.

33. The method, antibody, polypeptide or use according to any one of claims 1 to 3 or 7 to 9, wherein the antibody or the polypeptide is administered with an effective amount 3F f an immunosuppressive agent. [IADayLib\LIBI-]j08724.doc:MCC 63

34. The method, antibody, polypeptide or use according to claim 33, wherein the immunosuppressive agent is cyclosporine.

The method, antibody, polypeptide or use according to claim 33, wherein the immunosuppressive agent is prednisone.

36. The method, antibody, polypeptide or use according to claim 33, wherein the immunosuppressant agent is prednisone and cyclosporine.

37. A method for improving tolerance of transplanted allograft or xenograft tissue in a human, comprising administering a monoclonal anti-LFA-3 antibody or a soluble protein that binds CD2 to a human in need of such method.

38. A monoclonal anti-LFA-3 antibody or a soluble protein that binds CD2 when used to improve tolerance of transplanted allograft or xenograft tissue in a human in need of such improvement.

39. The use of a monoclonal anti-LFA-3 antibody or a soluble protein that binds CD2 for the preparation of a medicament for improving tolerance of transplanted allograft or xenograft tissue in a human in need of such improvement.

The method, antibody, soluble protein or use of any one of claims 37 to 39, wherein the transplanted allograft or xenograft tissue is perfused with said soluble protein prior to implantation into the human.

41. The method, anitbody, soluble protein or use of any one of claims 37 to 39, S. 20 wherein the soluble protein is administered with an effective amount of an immunosuppressive agent.

42. The method, antibody, soluble protein or use as claimed in any one of claims 37 S to 41, wherein the soluble protein that binds CD2 is a monoclonal anti-CD2 antibody.

43. The method, antibody, soluble protein or use as claimed in any one of claims 37 to 41, wherein the soluble protein that binds CD2 is a soluble LFA-3 polypeptide.

44. The method, antibody, soluble protein or use as claimed in any one of claims 37 to 41, wherein the soluble protein that binds CD2 is selected from Fab fragments, Fab' fragments, F(ab')2 fragments, F(v) fragments and intact immunoglobulin heavy chains of the anti-CD2 monoclonal antibody. S 30

45. A method for improving tolerance of transplanted allograft tissue or xenograft tissue comprising the steps of administering to a human, the graft tissue and a soluble LFA- 3 polypeptide.

46. A soluble LFA-3 polypeptide administered with a graft tissue, when used for '^i<improving tolerance of transplanted allograft or xenograft tissue in a human. [1:\DayLib\LIBH]08724.doc:MCC 64

47. The use of a soluble LFA-3 polypeptide for the preparation of a medicament to be administered with graft tissue, for improving tolerance of transplanted allograft or xenograft tissue in a human. Dated 29 October, 1999 Biogen, Inc. Patent Attorneys for the Applicant/Nominated Person SPRUSON FERGUSON 0 a. 0 S S S* S. SS S S 55*555 S S *555* S S. 0. S. S [I:\DayLib\L1BH]08724.doc:MCC